AU2020442490A1 - Process for generating genetically engineered autologous T cells - Google Patents
Process for generating genetically engineered autologous T cells Download PDFInfo
- Publication number
- AU2020442490A1 AU2020442490A1 AU2020442490A AU2020442490A AU2020442490A1 AU 2020442490 A1 AU2020442490 A1 AU 2020442490A1 AU 2020442490 A AU2020442490 A AU 2020442490A AU 2020442490 A AU2020442490 A AU 2020442490A AU 2020442490 A1 AU2020442490 A1 AU 2020442490A1
- Authority
- AU
- Australia
- Prior art keywords
- cells
- cell
- bioreactor
- soluble
- rocking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 300
- 238000000034 method Methods 0.000 title claims description 151
- 230000008569 process Effects 0.000 title description 34
- 238000004519 manufacturing process Methods 0.000 claims abstract description 31
- 210000004027 cell Anatomy 0.000 claims description 1044
- 239000001963 growth medium Substances 0.000 claims description 145
- 229940126530 T cell activator Drugs 0.000 claims description 99
- 230000001965 increasing effect Effects 0.000 claims description 90
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 claims description 78
- 239000013598 vector Substances 0.000 claims description 77
- 102000004127 Cytokines Human genes 0.000 claims description 73
- 108090000695 Cytokines Proteins 0.000 claims description 73
- 108090000623 proteins and genes Proteins 0.000 claims description 66
- 102000004169 proteins and genes Human genes 0.000 claims description 63
- 238000010361 transduction Methods 0.000 claims description 62
- 230000026683 transduction Effects 0.000 claims description 61
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 60
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 60
- 108010002350 Interleukin-2 Proteins 0.000 claims description 59
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 54
- 108091008874 T cell receptors Proteins 0.000 claims description 53
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 49
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 49
- 238000003306 harvesting Methods 0.000 claims description 44
- 239000012190 activator Substances 0.000 claims description 39
- 108010002586 Interleukin-7 Proteins 0.000 claims description 36
- 238000012546 transfer Methods 0.000 claims description 36
- 108700019146 Transgenes Proteins 0.000 claims description 35
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 34
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 34
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 33
- 230000010412 perfusion Effects 0.000 claims description 33
- 210000000265 leukocyte Anatomy 0.000 claims description 32
- 102100030704 Interleukin-21 Human genes 0.000 claims description 27
- 108010074108 interleukin-21 Proteins 0.000 claims description 27
- 108091033319 polynucleotide Proteins 0.000 claims description 26
- 102000040430 polynucleotide Human genes 0.000 claims description 26
- 239000002157 polynucleotide Substances 0.000 claims description 26
- 239000013603 viral vector Substances 0.000 claims description 26
- 238000011081 inoculation Methods 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 23
- 102000000844 Cell Surface Receptors Human genes 0.000 claims description 22
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 22
- 238000002617 apheresis Methods 0.000 claims description 21
- 210000003743 erythrocyte Anatomy 0.000 claims description 20
- 230000034659 glycolysis Effects 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 15
- 102000003812 Interleukin-15 Human genes 0.000 claims description 13
- 108090000172 Interleukin-15 Proteins 0.000 claims description 13
- 210000005259 peripheral blood Anatomy 0.000 claims description 12
- 239000011886 peripheral blood Substances 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 11
- 210000003714 granulocyte Anatomy 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 230000002463 transducing effect Effects 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 102000013814 Wnt Human genes 0.000 claims description 9
- 108050003627 Wnt Proteins 0.000 claims description 9
- 238000007710 freezing Methods 0.000 claims description 9
- 230000008014 freezing Effects 0.000 claims description 9
- 230000037361 pathway Effects 0.000 claims description 9
- 238000011534 incubation Methods 0.000 claims description 8
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 7
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 claims description 7
- 230000000890 antigenic effect Effects 0.000 claims description 7
- 238000005138 cryopreservation Methods 0.000 claims description 7
- 230000001177 retroviral effect Effects 0.000 claims description 7
- 238000001802 infusion Methods 0.000 claims description 6
- 210000000948 non-nucleated cell Anatomy 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000010257 thawing Methods 0.000 claims description 3
- 101100273713 Homo sapiens CD2 gene Proteins 0.000 claims description 2
- 238000002659 cell therapy Methods 0.000 abstract description 15
- 235000018102 proteins Nutrition 0.000 description 53
- 230000004913 activation Effects 0.000 description 48
- 239000007789 gas Substances 0.000 description 48
- 230000035899 viability Effects 0.000 description 40
- 210000000130 stem cell Anatomy 0.000 description 34
- 238000005516 engineering process Methods 0.000 description 33
- 239000000523 sample Substances 0.000 description 30
- 230000003068 static effect Effects 0.000 description 29
- 230000010261 cell growth Effects 0.000 description 27
- VPVLEBIVXZSOMQ-UHFFFAOYSA-N 3-[[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol Chemical compound NC1=CC=CC(C=2NC3=NC=NC(OC=4C=C(O)C=CC=4)=C3C=2)=C1 VPVLEBIVXZSOMQ-UHFFFAOYSA-N 0.000 description 25
- 102000008100 Human Serum Albumin Human genes 0.000 description 25
- 108091006905 Human Serum Albumin Proteins 0.000 description 25
- 238000012545 processing Methods 0.000 description 22
- -1 4,6-disubstituted pyrrolopyrimidine Chemical class 0.000 description 19
- 238000000926 separation method Methods 0.000 description 18
- 239000000427 antigen Substances 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 15
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 14
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 14
- 210000001772 blood platelet Anatomy 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 13
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 13
- 230000012010 growth Effects 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 11
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000012636 effector Substances 0.000 description 11
- 239000005090 green fluorescent protein Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 10
- 239000000306 component Substances 0.000 description 10
- 230000002147 killing effect Effects 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 9
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 9
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 9
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 238000011109 contamination Methods 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 210000000822 natural killer cell Anatomy 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000006044 T cell activation Effects 0.000 description 8
- 238000010364 biochemical engineering Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 7
- 229920001917 Ficoll Polymers 0.000 description 7
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 7
- 230000024245 cell differentiation Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000005484 gravity Effects 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 150000007523 nucleic acids Chemical group 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 6
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 210000000581 natural killer T-cell Anatomy 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 5
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 5
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 5
- 102000000704 Interleukin-7 Human genes 0.000 description 5
- 241000713666 Lentivirus Species 0.000 description 5
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000000139 costimulatory effect Effects 0.000 description 5
- 239000012595 freezing medium Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 108050008874 Annexin Proteins 0.000 description 4
- 102000000412 Annexin Human genes 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 4
- 102100022339 Integrin alpha-L Human genes 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 4
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000006037 cell lysis Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000013394 immunophenotyping Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 102100038078 CD276 antigen Human genes 0.000 description 3
- 102100025221 CD70 antigen Human genes 0.000 description 3
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101150046249 Havcr2 gene Proteins 0.000 description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 3
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 3
- 102100032818 Integrin alpha-4 Human genes 0.000 description 3
- 102100032816 Integrin alpha-6 Human genes 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 241000593312 Selfia Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000006727 cell loss Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000010977 unit operation Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 108700012439 CA9 Proteins 0.000 description 2
- 102100024263 CD160 antigen Human genes 0.000 description 2
- 102100038077 CD226 antigen Human genes 0.000 description 2
- 101710185679 CD276 antigen Proteins 0.000 description 2
- 102100022529 Cadherin-19 Human genes 0.000 description 2
- 101710196922 Cadherin-19 Proteins 0.000 description 2
- 102100036360 Cadherin-3 Human genes 0.000 description 2
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 2
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 2
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 2
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102100025323 Integrin alpha-1 Human genes 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108090000015 Mesothelin Proteins 0.000 description 2
- 102000003735 Mesothelin Human genes 0.000 description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 102100029197 SLAM family member 6 Human genes 0.000 description 2
- 102100027744 Semaphorin-4D Human genes 0.000 description 2
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 2
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 2
- 102100024586 Tumor necrosis factor ligand superfamily member 14 Human genes 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000011130 autologous cell therapy Methods 0.000 description 2
- WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000011437 continuous method Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 230000006545 glycolytic metabolism Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 238000007885 magnetic separation Methods 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- WEYNBWVKOYCCQT-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)thio]ethyl}urea Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(=O)NC1=CC=C(C)C(Cl)=C1 WEYNBWVKOYCCQT-UHFFFAOYSA-N 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- 108091007505 ADAM17 Proteins 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 102100021305 Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 Human genes 0.000 description 1
- 101710137115 Adenylyl cyclase-associated protein 1 Proteins 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 description 1
- 101710170638 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Proteins 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 238000012815 AlphaLISA Methods 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 101100288313 Arabidopsis thaliana KTI4 gene Proteins 0.000 description 1
- 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 description 1
- 101710095183 B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 1
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 description 1
- 108010056102 CD100 antigen Proteins 0.000 description 1
- 108010017009 CD11b Antigen Proteins 0.000 description 1
- 108010046080 CD27 Ligand Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108010058905 CD44v6 antigen Proteins 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- 108010032795 CD8 receptor Proteins 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 101710139831 CD82 antigen Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 101710097534 Cadherin-3 Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 102100030886 Complement receptor type 1 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 1
- 102000012804 EPCAM Human genes 0.000 description 1
- 101150084967 EPCAM gene Proteins 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 1
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 1
- 101710088083 Glomulin Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 102100032530 Glypican-3 Human genes 0.000 description 1
- 108050007237 Glypican-3 Proteins 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101001042227 Homo sapiens Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000762242 Homo sapiens Cadherin-15 Proteins 0.000 description 1
- 101000714553 Homo sapiens Cadherin-3 Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 1
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 1
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 description 1
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 description 1
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 description 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 1
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 1
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 1
- 101001036686 Homo sapiens Melanoma-associated antigen B2 Proteins 0.000 description 1
- 101001057131 Homo sapiens Melanoma-associated antigen D4 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 1
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101000874141 Homo sapiens Probable ATP-dependent RNA helicase DDX43 Proteins 0.000 description 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 1
- 101001109419 Homo sapiens RNA-binding protein NOB1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 1
- 101000654734 Homo sapiens Septin-4 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101001056234 Homo sapiens Sperm mitochondrial-associated cysteine-rich protein Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000648075 Homo sapiens Trafficking protein particle complex subunit 1 Proteins 0.000 description 1
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000830594 Homo sapiens Tumor necrosis factor ligand superfamily member 14 Proteins 0.000 description 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 101710123134 Ice-binding protein Proteins 0.000 description 1
- 101710082837 Ice-structuring protein Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108050002021 Integrator complex subunit 2 Proteins 0.000 description 1
- 102100022341 Integrin alpha-E Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 108010030465 Integrin alpha6beta1 Proteins 0.000 description 1
- 102100033016 Integrin beta-7 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100033461 Interleukin-17A Human genes 0.000 description 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 1
- 102100039479 Melanoma-associated antigen B2 Human genes 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 1
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 description 1
- 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 description 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- 102100035724 Probable ATP-dependent RNA helicase DDX43 Human genes 0.000 description 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100022491 RNA-binding protein NOB1 Human genes 0.000 description 1
- 101150066717 Rara gene Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
- 102100029216 SLAM family member 5 Human genes 0.000 description 1
- 102100029198 SLAM family member 7 Human genes 0.000 description 1
- 102100032743 Septin-4 Human genes 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710163413 Signaling lymphocytic activation molecule Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000000277 Splenic Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 102100035721 Syndecan-1 Human genes 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 101150057140 TACSTD1 gene Proteins 0.000 description 1
- 108700019889 TEL-AML1 fusion Proteins 0.000 description 1
- 102100033082 TNF receptor-associated factor 3 Human genes 0.000 description 1
- 101150033985 TPI gene Proteins 0.000 description 1
- 101150032817 TPI1 gene Proteins 0.000 description 1
- 102100033740 Tenomodulin Human genes 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100025256 Trafficking protein particle complex subunit 1 Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 102100033598 Triosephosphate isomerase Human genes 0.000 description 1
- 102100033579 Trophoblast glycoprotein Human genes 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108700020467 WT1 Proteins 0.000 description 1
- 101150084041 WT1 gene Proteins 0.000 description 1
- 102100022748 Wilms tumor protein Human genes 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 229950009579 axicabtagene ciloleucel Drugs 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011198 co-culture assay Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- PGUYAANYCROBRT-UHFFFAOYSA-N dihydroxy-selanyl-selanylidene-lambda5-phosphane Chemical compound OP(O)([SeH])=[Se] PGUYAANYCROBRT-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 101150090422 gsk-3 gene Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000019261 negative regulation of glycolysis Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000011338 personalized therapy Methods 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- JRPHGDYSKGJTKZ-UHFFFAOYSA-K selenophosphate Chemical compound [O-]P([O-])([O-])=[Se] JRPHGDYSKGJTKZ-UHFFFAOYSA-K 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000013169 thromboelastometry Methods 0.000 description 1
- 108010078373 tisagenlecleucel Proteins 0.000 description 1
- 229950007137 tisagenlecleucel Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to production of autologous genetically engineered T cells for use in cell therapy applications.
Description
PROCESS FOR GENERATING GENETICALLY ENGINEERED AUTOLOGOUS T CELLS
FIELD OF DISCLOSURE
The present invention relates to production of autologous genetically engineered T cells for use in cell therapy applications.
BACKGROUND
Adoptive T-cell therapy makes use of genetically engineered T cells and has been shown to be an effective and powerful therapeutic treatment in certain hematological indications. Autologous T cells are genetically engineered to express one or more cell surface receptors, such as chimeric antigen receptors (CARs) or T-cell receptors (TCRs), that recognize proteins of interest associated with the surface of target cells, while retaining and/or enhancing their ability to recognize and kill the target cells. In addition to the genetically engineered T cells’ ability to recognize and destroy the targeted cells, successful adoptive T- cell therapy benefits from the T cells’ ability to persist in the patient and continue to proliferate in response to a target antigen. Genetically engineered autologous T cells have shown great success in treating a wide range of cancers.
For autologous T cell therapeutics, the product is a live cell from a specific patient that will be returned to that patient. As such, autologous cell production is more challenging than conventional biopharmaceutical processes because one lot is manufactured for one patient. Manufacturing can only start when a patient sample is received and care must be taken that the cells are returned to the patient without significant modifications that make the cells a risk rather than an efficacious treatment. Production is more hands on and labor intensive, and performed multiple times at a small scale, to produce cells at sufficient quantity and quality. Donor to donor variability increases the complexity, because the starting material is different for each new lot produced.
The specifications for assessing an autologous drug product are also different from a typical recombinant protein drug product. For autologous T-cell therapeutics, product purity, cell phenotype, percent engineered T cells, potency and specificity, are the parameters tested. Integrated closed process platforms using complex automated systems are being developed but carry a high capital investment. Developing an efficient, scalable, reliable, and cost-effective process remains one of the main challenges for the advancement of use of autologous cells as a therapeutic, which is for the most part a highly manual process.
There is a need for production processes for generating T-cell therapeutics, particularly autologous T-cell therapeutics, that reduce risk of contamination, cost, facility footprint, and the inefficiencies and complexity of current manufacturing processes. Autologous T-cell therapies are forecast to be in the range of $350,000 to $475,000 per patient, not including hospital-associated costs. If genetically engineered autologous T cells are to achieve their full clinical and commercial potential, the challenges facing production of clinical grade cells at commercially relevant quantities and quality must be overcome. The
invention described herein meets this need by providing an efficient and effective method manufacture to genetically engineered T cells for autologous cell therapy.
BRIEF SUMMARY OF THE INVENTION
The invention provides a method for producing genetically engineered autologous T cells expressing at least one protein of interest, the method comprising inoculating a closed single use bioreactor bag containing culture media with apheresed donor cells and one or more soluble T cell activators, wherein the bioreactor bag is part of a rocking bioreactor platform, culturing the cells in the closed single use bioreactor bag continuously rocking at a rate of about 2 RPM, transducing the cells in the closed single use bioreactor bag with at least one soluble viral vector comprising a polynucleotide which encodes the protein of interest continuously rocking at a rate of about 2 RPM, and expanding the cells in the closed single use bioreactor bag at a rocking rate of about 2 RPM and increasing the culture volume and rocking rate as needed to maintain the culture until harvest. In one embodiment the apheresed donor cells comprise cells from peripheral blood. In a related embodiment the apheresed donor cells comprise nucleated and non- nucleated cells. In one embodiment the apheresed donor cells comprise leukocytes and erythrocytes. In a related embodiment the apheresed donor cells also comprise granulocytes and/or platelets. In one embodiment the apheresis is leukapheresis. In one embodiment the apheresed donor cells are washed and resuspended in a culture media. In one embodiment at least one T cell activator is an anti CD3 antibody or binding fragments thereof. In yet another embodiment the T cell activator comprises an anti CD3 antibody and an anti CD28 antibody, or binding fragments thereof. In one embodiment the T cell activator comprises at least an anti CD3 antibody, an anti CD28 antibody, and an anti CD2 antibody, or binding fragments thereof. In another embodiment the T cell activator comprises at least an anti-human CD3 monospecific tetrameric antibody complex, an anti-human CD28 monospecific tetrameric antibody complex, and an anti human CD2 monospecific tetrameric antibody complex. In another embodiment the concentration of at least one soluble T cell activator is at least 0.001 pg/ml to at least 10 pg/ml. In a related embodiment the concentration of at least one soluble T cell activator is at least 0.1 pg/ml to at least 5 pg/ml. In yet another embodiment at least one soluble T -cell activator is bound to at least one donor cell at the time of inoculation. In another embodiment the apheresed donor cells are incubated with one or more soluble T cell activators prior to inoculating into the bioreactor bag. In a related embodiment the incubation is for a sufficient time to allow for saturation of binding of one or more soluble T cell activator to the apheresed donor cells prior to inoculation. In a related embodiment the apheresed donor cells and one or more soluble T cell activators are incubated in a transfer bag. In a related embodiment the volume of culture media in the transfer bag is about 5 ml to about 50 ml. In a related embodiment the volume of culture media in the transfer bag is about 5 ml to about 10 ml. In a related embodiment the apheresed donor cells are incubated with one or more T cell activators for at least 30 minutes or more. In a related embodiment the apheresed donor cells are incubated with one or more T cell activators for at least 1 hour. In one embodiment the number of nucleated
cells within the apheresed donor cells is about 1.0E9 to about 1.3E9. In one embodiment the number of nucleated cells within the apheresed donor cells is about 1.2E9. In one embodiment the bioreactor bag is inoculated with apheresed donor cells at a cell density of about 1E6 to about 5E6 nucleated cells/ml. In a related embodiment the bioreactor bag is inoculated with apheresed donor cells at a cell density of about 2E6. In one embodiment the bioreactor bag contains at least 300 ml to at least 400 ml of culture media at inoculation. In a related embodiment the bioreactor bag contains at least 300 ml of culture media at inoculation. In one embodiment the apheresed donor cells are cultured in the bioreactor bag for about 12- 24 hours. In one embodiment the culture media comprises at least one soluble cytokine. In a related embodiment the soluble cytokine selected from IL-2, IL-7, IL-15, or IL-21. In a related embodiment at least one soluble cytokine is IL-2. In a related embodiment the IL-2 is at a concentration of about 250 IU/ml to about 350 IU/ml. In a related embodiment the IL-2 is at a concentration of about 300 IU/ml. In a related embodiment the soluble cytokine is IL-7 in combination with IL-15 or IL-21. In a related embodiment the concentration of at least one cytokine is at least 5ng/ml to at least 30ng/ml. In a related embodiment the concentration of at least one cytokine is at least lOng/ml to at least 20ng/ml. In one embodiment the culture media also comprises a WNT pathway activator. In a related embodiment the WNT pathway activator is TWS117. In a related embodiment the culture media comprises a mixture of soluble TWS117, IL-7, and IL-21. In one embodiment the culture media also comprises a soluble glycolysis inhibitor. In a related embodiment the soluble glycolysis inhibitor is 2-deoxy-D-glucose (2-DG). In one embodiment the viral vector is a retroviral vector. In one embodiment the viral vector is a lentiviral vector. In one embodiment the lentiviral vector is added at a MOI of 0.25 - 10. In a related embodiment the lentiviral vector is added at a MOI of 1. In one embodiment the cells are transduced for about 20-24 hours. In one embodiment following transduction, half of the culture media is removed from the bioreactor bag and replaced with an equal volume of fresh culture media. In a related embodiment the culture is incubated for about 12-24 hours. In one embodiment during expansion, fresh culture media is added to the bioreactor by fed batch/perfusion feeding and/or by perfusion. In one embodiment during expansion the culture is perfused at a rate is one bioreactor bag volume per day. In one embodiment the cells are expanded the volume of the culture media in bioreactor is incrementally increased to 1 liter during expansion. In one embodiment as the cells are expanded the volume of the culture media is incrementally increased to maintain a cell density of at least 2E6 nucleated cells/ml. In one embodiment as the cells are expanded the volume of the culture media in bioreactor is incrementally increased to 1 liter during expansion to maintain a cell density of at least 4E6 nucleated cells/ml. In one embodiment as the cells are expanded the rocking rate is incrementally increased to 6 RPM. In one embodiment at the start of expansion, the volume of culture media in the single use closed bioreactor bag is 300 ml rocking at a rate of 2 rpm at a 2° angle. In one embodiment the culture in the single use closed bioreactor bag is maintained at about 80 - 100% O2. In one embodiment the cells are expanded for 7 to 14 days. In one embodiment the culture, transduction, and/or expansion steps are performed at 34-37°C. In one embodiment the protein of interest is a cell surface receptor. In a related embodiment the cell surface
receptor a T cell receptor, or chimeric antigen receptor. In a related embodiment the cell surface receptor recognizes an antigenic target associated with a target cell. In a related embodiment the target cell is a cancer cell. In one embodiment the genetically engineered autologous T cells are used to treat an indication in a patient in need.
The invention provides a pharmaceutical composition comprising the genetically engineered autologous T cells made using the method described above.
The invention provides a method of treating an indication in a patient in need, comprising administering to the patient the pharmaceutical composition as described above.
The invention provides a method for increasing the transgene expression in genetically engineered autologous T cells expressing a protein of interest, the method comprising inoculating a closed single use bioreactor bag containing culture media with apheresed donor cells and one or more soluble T cell activators, wherein at least one soluble T-cell activator is bound to at least one donor cell at the time of inoculation and the bioreactor bag is part of a rocking bioreactor platform, culturing the cells in the closed single use bioreactor bag continuously rocking at a rate of about 2 RPM, transducing the cells in the closed single use bioreactor bag with at least one soluble viral vector comprising a polynucleotide which encodes the protein of interest continuously rocking at a rate of about 2 RPM, and expanding the cells in the closed single use bioreactor bag at a rocking rate of about 2 RPM and increasing the culture volume and rocking the rate as needed to maintain the culture until harvest, wherein the transgene expression is greater than the transgene expression of genetically engineered autologous T cells derived from an enriched population of T cells from the same apheresed donor cells and expressing the same protein of interest. In one embodiment the apheresed donor cells comprise cells from peripheral blood. In a related embodiment the apheresed donor cells comprise nucleated and non-nucleated cells. In one embodiment the apheresed donor cells comprise leukocytes and erythrocytes. In a related embodiment the apheresed donor cells also comprise granulocytes and/or platelets. In one embodiment the apheresis is leukapheresis. In one embodiment the apheresed donor cells are washed and resuspended in a culture media. In one embodiment at least one T cell activator is an anti CD3 antibody or binding fragments thereof. In yet another embodiment the T cell activator comprises an anti CD3 antibody and an anti CD28 antibody, or binding fragments thereof. In one embodiment the T cell activator comprises at least an anti CD3 antibody, an anti CD28 antibody, and an anti CD2 antibody, or binding fragments thereof. In another embodiment the T cell activator comprises at least an anti-human CD3 monospecific tetrameric antibody complex, an anti-human CD28 monospecific tetrameric antibody complex, and an anti-human CD2 monospecific tetrameric antibody complex. In another embodiment the concentration of at least one soluble T cell activator is at least 0.001 pg/ml to at least 10 pg/ml. In a related embodiment the concentration of at least one soluble T cell activator is at least 0.1 pg/ml to at least 5 pg/ml. In another embodiment the apheresed donor cells are incubated with one or more soluble T cell activators prior to inoculating into the bioreactor bag. In a related embodiment the incubation is for a sufficient time to allow for saturation of binding of one or more soluble T cell activator to the apheresed donor cells prior to inoculation. In a related embodiment the apheresed donor cells and
one or more soluble T cell activators are incubated in a transfer bag. In a related embodiment the volume of culture media in the transfer bag is about 5 ml to about 50 ml. In a related embodiment the volume of culture media in the transfer bag is about 5 ml to about 10 ml. In a related embodiment the apheresed donor cells are incubated with one or more T cell activators for at least 30 minutes or more. In a related embodiment the apheresed donor cells are incubated with one or more T cell activators for at least 1 hour. In one embodiment the number of nucleated cells within the apheresed donor cells is about 1.0E9 to about 1.3E9. In one embodiment the number of nucleated cells within the apheresed donor cells is about 1.2E9. In one embodiment the bioreactor bag is inoculated with apheresed donor cells at a cell density of about 1E6 to about 5E6 nucleated cells/ml. In a related embodiment the bioreactor bag is inoculated with apheresed donor cells at a cell density of about 2E6. In one embodiment the bioreactor bag contains at least 300 ml to at least 400 ml of culture media at inoculation. In a related embodiment the bioreactor bag contains at least 300 ml of culture media at inoculation. In one embodiment the apheresed donor cells are cultured in the bioreactor bag for about 12-24 hours. In one embodiment the culture media comprises at least one soluble cytokine. In a related embodiment the soluble cytokine selected from IL-2, IL-7, IL-15, or IL-21. In a related embodiment at least one soluble cytokine is IL-2. In a related embodiment the IL-2 is at a concentration of about 250 IU/ml to about 350 IU/ml. In a related embodiment the IL-2 is at a concentration of about 300 IU/ml. In a related embodiment the soluble cytokine is IL-7 in combination with IL-15 or IL-21. In a related embodiment the concentration of at least one cytokine is at least 5ng/ml to at least 30ng/ml. In a related embodiment the concentration of at least one cytokine is at least lOng/ml to at least 20ng/ml. In one embodiment the culture media also comprises a WNT pathway activator. In a related embodiment the WNT pathway activator is TWS117. In a related embodiment the culture media comprises a mixture of soluble TWS117, IL-7, and IL-21. In one embodiment the culture media also comprises a soluble glycolysis inhibitor. In a related embodiment the soluble glycolysis inhibitor is 2- deoxy-D-glucose (2-DG). In one embodiment the viral vector is a retroviral vector. In one embodiment the viral vector is a lentiviral vector. In one embodiment the lentiviral vector is added at a MOI of 0.25 - 10. In a related embodiment the lentiviral vector is added at a MOI of 1. In one embodiment the cells are transduced for about 20-24 hours. In one embodiment following transduction, half of the culture media is removed from the bioreactor bag and replaced with an equal volume of fresh culture media. In a related embodiment the culture is incubated for about 12-24 hours. In one embodiment during expansion, fresh culture media is added to the bioreactor by fed batch/perfusion feeding and/or by perfusion. In one embodiment during expansion the culture is perfused at a rate is one bioreactor bag volume per day. In one embodiment the cells are expanded the volume of the culture media in bioreactor is incrementally increased to 1 liter during expansion. In one embodiment as the cells are expanded the volume of the culture media is incrementally increased to maintain a cell density of at least 2E6 nucleated cells/ml. In one embodiment as the cells are expanded the volume of the culture media in bioreactor is incrementally increased to 1 liter during expansion to maintain a cell density of at least 4E6 nucleated cells/ml. In one embodiment as the cells are expanded the rocking rate is incrementally increased to 6 RPM. In one embodiment
at the start of expansion, the volume of culture media in the single use closed bioreactor bag is 300 ml rocking at a rate of 2 rpm at a 2° angle. In one embodiment the culture in the single use closed bioreactor bag is maintained at about 80 - 100% O2. In one embodiment the cells are expanded for 7 to 14 days. In one embodiment the culture, transduction, and/or expansion steps are performed at 34-37°C. In one embodiment the protein of interest is a cell surface receptor. In a related embodiment the cell surface receptor a T cell receptor, or chimeric antigen receptor. In a related embodiment the cell surface receptor recognizes an antigenic target associated with a target cell. In a related embodiment the target cell is a cancer cell. In one embodiment the genetically engineered autologous T cells are used to treat an indication in a patient in need.
The invention provides a method of treating a patient with genetically engineered autologous T cells expressing a protein of interest comprising, incubating apheresed cells from the patient with one or more T cell activators selected from the group consisting of an anti CD3 antibody, an anti CD2 antibody, and an anti CD28 antibody or binding fragments thereof, to allow for saturation of antibody binding, inoculating a closed single use bioreactor bag containing culture media with the apheresed cells, wherein the bioreactor bag is part of a rocking bioreactor platform, culturing the cells in the closed single use bioreactor bag continuously rocking at a rate of about 2 RPM, transducing the cells in the closed single use bioreactor bag with at least one soluble viral vector comprising a polynucleotide which encodes the protein of interest continuously rocking at a rate of about 2 RPM, and expanding the cells in the closed single use bioreactor bag at a rocking rate of about 2 RPM, increasing the culture volume and rocking the rate as needed to maintain the culture at a desired cell density until harvest, harvesting and formulating the cells for cryopreservation, freezing the cells and storing until needed for administering to the patient, thawing and resuspending the cells in a suitable media for infusion, and reintroducing a pharmaceutically effective amount of the genetically engineered autologous T cells expressing the protein of interest into the patient. In one embodiment the apheresed donor cells comprise cells from peripheral blood. In a related embodiment the apheresed donor cells comprise nucleated and non-nucleated cells. In one embodiment the apheresed donor cells comprise leukocytes and erythrocytes. In a related embodiment the apheresed donor cells also comprise granulocytes and/or platelets. In one embodiment the apheresis is leukapheresis. In one embodiment the apheresed donor cells are washed and resuspended in a culture media. In one embodiment at least one T cell activator is an anti CD3 antibody or binding fragments thereof. In yet another embodiment the T cell activator comprises an anti CD3 antibody and an anti CD28 antibody, or binding fragments thereof. In one embodiment the T cell activator comprises at least an anti CD3 antibody, an anti CD28 antibody, and an anti CD2 antibody, or binding fragments thereof. In another embodiment the T cell activator comprises at least an anti-human CD3 monospecific tetrameric antibody complex, an anti-human CD28 monospecific tetrameric antibody complex, and an anti-human CD2 monospecific tetrameric antibody complex. In another embodiment the concentration of at least one soluble T cell activator is at least 0.001 pg/ml to at least 10 pg/ml. In a related embodiment the concentration of at least one soluble T cell activator is at least 0.1 pg/ml to at least 5 pg/ml. In yet another embodiment at least one
soluble T-cell activator is bound to at least one donor cell at the time of inoculation. In a related embodiment the incubation is for a sufficient time to allow for saturation of binding of one or more soluble T cell activator to the apheresed donor cells prior to inoculation. In a related embodiment the apheresed donor cells and one or more soluble T cell activators are incubated in a transfer bag. In a related embodiment the volume of culture media in the transfer bag is about 5 ml to about 50 ml. In a related embodiment the volume of culture media in the transfer bag is about 5 ml to about 10 ml. In a related embodiment the apheresed donor cells are incubated with one or more T cell activators for at least 30 minutes or more. In a related embodiment the apheresed donor cells are incubated with one or more T cell activators for at least 1 hour. In one embodiment the number of nucleated cells within the apheresed donor cells is about 1.0E9 to about 1.3E9. In one embodiment the number of nucleated cells within the apheresed donor cells is about 1.2E9. In one embodiment the bioreactor bag is inoculated with apheresed donor cells at a cell density of about 1E6 to about 5E6 nucleated cells/ml. In a related embodiment the bioreactor bag is inoculated with apheresed donor cells at a cell density of about 2E6. In one embodiment the bioreactor bag contains at least 300 ml to at least 400 ml of culture media at inoculation. In a related embodiment the bioreactor bag contains at least 300 ml of culture media at inoculation. In one embodiment the apheresed donor cells are cultured in the bioreactor bag for about 12-24 hours. In one embodiment the culture media comprises at least one soluble cytokine. In a related embodiment the soluble cytokine selected from IL-2, IL-7, IL-15, or IL-21. In a related embodiment at least one soluble cytokine is IL-2. In a related embodiment the IL-2 is at a concentration of about 250 IU/ml to about 350 IU/ml. In a related embodiment the IL-2 is at a concentration of about 300 IU/ml. In a related embodiment the soluble cytokine is IL-7 in combination with IL-15 or IL-21. In a related embodiment the concentration of at least one cytokine is at least 5ng/ml to at least 30ng/ml. In a related embodiment the concentration of at least one cytokine is at least lOng/ml to at least 20ng/ml. In one embodiment the culture media also comprises a WNT pathway activator. In a related embodiment the WNT pathway activator is TWS117. In a related embodiment the culture media comprises a mixture of soluble TWS117, IL-7, and IL-21. In one embodiment the culture media also comprises a soluble glycolysis inhibitor. In a related embodiment the soluble glycolysis inhibitor is 2- deoxy-D-glucose (2-DG). In one embodiment the viral vector is a retroviral vector. In one embodiment the viral vector is a lentiviral vector. In one embodiment the lentiviral vector is added at a MOI of 0.25 - 10. In a related embodiment the lentiviral vector is added at a MOI of 1. In one embodiment the cells are transduced for about 20-24 horns. In one embodiment following transduction, half of the culture media is removed from the bioreactor bag and replaced with an equal volume of fresh culture media. In a related embodiment the culture is incubated for about 12-24 hours. In one embodiment during expansion, fresh culture media is added to the bioreactor by fed batch/perfusion feeding and/or by perfusion. In one embodiment during expansion the culture is perfused at a rate is one bioreactor bag volume per day. In one embodiment the cells are expanded the volume of the culture media in bioreactor is incrementally increased to 1 liter dining expansion. In one embodiment as the cells are expanded the volume of the culture media is incrementally increased to maintain a cell density of at least 2E6 nucleated cells/ml. In one embodiment
as the cells are expanded the volume of the culture media in bioreactor is incrementally increased to 1 liter during expansion to maintain a cell density of at least 4E6 nucleated cells/ml. In one embodiment as the cells are expanded the rocking rate is incrementally increased to 6 RPM. In one embodiment at the start of expansion, the volume of culture media in the single use closed bioreactor bag is 300 ml rocking at a rate of 2 rpm at a 2° angle. In one embodiment the culture in the single use closed bioreactor bag is maintained at about 80 - 100% O2. In one embodiment the cells are expanded for 7 to 14 days. In one embodiment the culture, transduction, and/or expansion steps are performed at 34-37°C. In one embodiment the protein of interest is a cell surface receptor. In a related embodiment the cell surface receptor a T cell receptor, or chimeric antigen receptor. In a related embodiment the cell surface receptor recognizes an antigenic target associated with a target cell. In a related embodiment the target cell is a cancer cell. In one embodiment the genetically engineered autologous T cells are used to treat an indication in a patient in need.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1. (A) Growth curve of cell expansion in Xuri W25 bioreactor supplemented with IL2 only or cocktail of IL7, IL21 , and TW S 119. (B) Viability of cell expanded in Xuri W25 bioreactor supplemented with IL2 only or IL7, IL21, and TWS119 cocktail.
Figure 2. T cell transgene expression from engineered T cells expressed in the three systems: Xuri W25 bioreactor (’’Xuri”), combination of static perfusion bag and Xuri W25 bioreactor (“Permeable Bag”) and G-Rex® plates (“G-Rex”).
Figure 3. Feukocyte subsets in harvested engineered T cells expressed in the three systems: Xuri W25 bioreactor (’’Xuri”), combination of static perfusion bag and Xuri W25 bioreactor (“Permeable Bag”) and G-Rex plates (“G-Rex”).
Figure 4. Percentage of T cells subsets on Day 5 (A) and Day 10 (B) from engineered T cells expressed in the three systems: Xuri W25 bioreactor (”Xuri”), combination of static perfusion bag and Xuri W25 bioreactor (“Permeable Bag”) and G-Rex plates (“G-Rex”).
Figure 5. Shows the cytotoxic function of engineered T cells characterized by their ability in target cell lysis (A), IFN-gamma release in response to target cells (B), and TNF-alpha release in response to target cells (C).
Figure 6. Resistance to target cell challenge of engineered T cells expressed in the three systems: Xuri W25 bioreactor (”Xuri”), combination of static perfusion bag and Xuri W25 bioreactor (“Permeable Bag”) and G-Rex plates (“G-Rex”). Annexin level (A), Tim3 (B).
Figure 7. Growth curve (A) and viability (B) for cells expanded in media supplemented with 2-DG (Media 1) and without 2-DG (Media 2).
Figure 8. Transgene expression of cells expanded in the media supplemented with 2-DG (Media 1) and without 2-DG (Media 2).
Figure 9. CD25 expression by cells expanded in the media supplemented with 2-DG (Media 1) and without 2-DG (Media 2).
Figure 10. Glucose (A) and lactate (B) concentrations in cultures supplemented with 2-DG (Media 1) and without 2-DG (Media 2).
Figure 11. T differentiation phenotyping of cells expanded media supplemented with (Media 1) and without 2-DG (Media 2).
Figure 12. Leukocyte subsets in harvested T cells of cells expanded media supplemented with (Media 1) and without 2-DG (Media 2).
Figure 13. Results from potency assays of engineered TCR T cells. (A) Cytotoxicity. (B) IFN-g. (C) T cell differentiation.
Figure 14. Transgene expression of T cells at harvest from enriched- and unenriched-process, gated on CD8+ cells (A) or CD4+ cells (B).
Figure 15. Vector copy number of TCR in CD4+ and CD8+ T cells.
Figure 16. Percentage of leukocytes and leukocyte subsets measured at the end of harvest.
Figure 17. T cell phenotype at harvest from the enriched- and unenriched- cells from three donors.
Figure 18. Growth curve (A) and viability (B) of cells in the bioreactor from enriched- and unenriched- donor cells.
Figure 19. Growth curve and viability of cells.
Figure 20. Percentage of leukocyte subsets at DayO and Day 10.
Figure 21. T cell differentiation during bioprocessing.
Figure 22 shows the expression of transgene in harvested T cells at cell surface level (A) and DNA level (B).
Figure 23. Percentage of killing of target cells at different effector to target cells (E: T) ratios.
Figure 24. IFN-gamma release of harvested cells in response to target cells.
Figure 25. Results of the titration of coated anti-CD3 (OKT3) antibody and pan T cell activation measured by CD69, CD35, and 4-1BB.
Figure 26. Results of stimulation of pan T cells with various soluble activators versus coated anti- CD3 as measured by CD69, CD25, and 4-1BB.
Figure 27. Transduction efficiency for the engineered T cells, Pan T cells (A) and apheresed donor cells (B).
Figure 28. Cell growth of cells activated by various activators.
Figure 29. Effect of culture conditions on transduction efficiency.
Figure 30. Cell density and transduction efficiency.
Figure 31. Multiplicity of infection for TCR transduction. (A) MOI of 1-10, (B) MOI of 0.25 to 2.
DETAILED DESCRIPTION OF THE INVENTION
Autologous T-cell therapy is a personalized therapy, the genetically engineered T cells being derived from the patient’s own cells, “autologous cells”, which are manipulated and returned to the patient. T cell or T lymphocyte refers to a type of lymphocyte (others are B cells and NK cells) that actively participates in the body’s immune response. While use of autologous cells reduces the risk of immunological responses, manufacturing a therapy at one lot per patient adds complexity and cost. Also, because autologous T-cell therapy is patient-centric, this treatment is unlike traditional biologic therapeutics, and is not suitable for large scale production and off-the-shelf use.
Autologous T-cell therapy involves treating patients with their own live T cells that have been engineered to express a protein of interest that recognizes a protein associated with a target cell. Autologous T cell manufacturing processes typically make use of multiple unit operations including semi-closed and/or closed steps, moving the patient’s cells between multiple vessels such as plates, flasks, containers, bags, or other types of vessels, typically gas permeable vessels, over the course of production. These transfers may involve movement of fluid from one vessel to another by means such as syringes or pipettes, centrifuges, and the like that can put unnecessary stress on the cells through shear forces and expose the cells to contaminants and loss. In addition, such vessels require manual transfer into and between equipment, such as cell separators, biosafety cabinets, and incubators.
As described herein, a method for producing genetically engineered autologous T cells that express a protein of interest has been developed that produces T cells of high purity, greater than 98%, with high transgene expression, greater than 45% on CD8 T cells, generates cell yields of greater than 10 billion with a viability of greater than 90% in a 10-day completely closed and continuous process. Starting with an apheresed donor sample, the T cells are selectively expanded from about 50% when harvested to greater than 98% following genetic manipulation and expansion of the activated cells. The resulting T cells are less differentiated and remain in a more stem-cell or memory-like phenotype which increases persistence and over all efficacy. The resulting cells are more potent in killing target cells and resistant target cell challenge.
While the growth rate and viability were equivalent to cells that were enriched prior to activation and transduction, the transduction was more efficient, and the function and efficacy of the cells produced directly from harvested donor cells were greater.
The genetically engineered autologous T cells were generated in a closed continuous rocking culture through the steps of activation, transduction, and expansion, using bioreactor capable of producing a rocking motion throughout. The rocking was tailored to the variances in bioreactor volume, (increasing
to 1 liter by the end of expansion), and oxygen levels as the cell density increased during the process. This ensured a sufficient mass transfer of oxygen and nutrients to support the high-density cultures in contrast to methods using static culture which must be grown at low cell density (< 2E6 cells/ml) due to limitations of the culture media under static conditions. While the cells that were rocked in a bioreactor bag and a commonly used static G-Rex® gas permeable culture system both had efficient oxygen transport, the G- Rex® system lacked the convection flow that transfers nutrients to cells in a timely manner. Also, the bioreactor bags can take advantage of perfusion of fresh media which supports very high cell densities, up to 50E6 cells/ml in some cases.
Compared to cells generated in static, gas permeable vessels or cultures generated using a combination of static (activation and transduction operations) and rocking (expansion operations) systems, the method described herein eliminated more than 30% of the hands-on work and greatly reduced the cost. Incubators and other support equipment that is essential for preparing and maintaining static cultures in gas permeable vessels are not necessary, reducing the manufacturing footprint and risk of contamination of the cells and the equipment from the necessary handling and manipulation that these static cultures require. While the growth rate and viability of the cells generated by these systems were equivalent, the transgene expression, function and efficacy of the cells generated by the method described herein was greater than for the cells generated in cultures making use of gas permeable vessels in static or hybrid static/rocking cultures.
The donor may be any subject from which a sample of blood cells is needed for producing genetically engineered autologous T cells. The donor may be a patient in need of treatment with a population of cells generated by the method described herein (i.e., an autologous donor).
The donor cells may be harvested from the circulating peripheral blood by any suitable method used in the art such as extracorporeal methods, venipuncture, or other blood collection methods by which a sample of blood is typically obtained. In one embodiment, the donor cells are harvested by apheresis. Apheresis refers to the withdrawal of blood from a donor, which is separated into cellular and soluble components, removing certain desired components from the blood and then returning the remainder of the blood to the donor. Where T cells are a desired cell type, such as for cell therapy applications, leukapheresis, an apheresis process which preferentially removes white blood cells (leukocytes) from the peripheral blood of a donor, is most often used. The harvested leukapheresis sample may be provided in a Leukopak® container. Multiple blood volumes are processed from the same donor to generate a full Leukopak®.
Apheresis separates the incoming blood into the various blood components using methods such as differential centrifugation. However, because there is a close range in the density between blood components, this will not result in pure cell populations, there will be residual cells in any sample collected by an apheresis process, and the quantities of these residual cells will increase as the volume of blood processed during the apheresis procedure increases. Cells harvested by leukapheresis will comprise
nucleated cells, such as leukocytes, including monocytes, dendritic cells, lymphocytes (T-, B-, and NK cells), and granulocytes, as well as megakaryocytes, and cells without a nucleus, such as erythrocytes and platelets. While the percentage of lymphocytes in the collected apheresed sample is more concentrated compared to whole blood, there will also be a significant number of other cells such as NK cells, red blood cells, platelets, and granulocytes in the sample as well.
Apheresed cells are frequently used as source for collecting blood-based cells, such as leukocytes and lymphocytes. However, since these samples include a mixture of blood cells, for example, Leukopack®s containing apheresed cells can contain tens of billions of red blood cells making the collected cell sample visibly red. Red blood cells are known to have an impact further processing of the cells in the sample, such as by drastically lower transfection rates when using electroporation, for example. “As there is inherent variability in the cell populations in these leukapheresis products, processes to remove unwanted cells or isolate specific populations of cells have been developed using a variety of technologies including physical separation via centrifugation, magnetic, fluorescent, as well as acoustic-based selection. Cells types can be separated based on size through centrifugation, with or without the use of density gradient media systems (such as Ficoll, for example), which enables removal of unwanted fractions of leukapheresis product such as granulocytes, platelets and remaining red blood cell contaminants.” Iyer et al., (2018) Frontiers in Medicine, Vol. 5, 150. It is common practice in production of autologous and allogenic T cells to further isolate, select, and/or enrich for desired cell populations or phenotypes from the apheresed sample before using the cells in a particular method or application related to cell therapy. The purpose of this further processing is to obtain a more highly defined population of cells, such as PBMCs, or specific lymphocyte populations, for uses such as T cell activation or expansion, see for example, Stroncek et al. Journal of Translational Medicine 2014, 12:241-249.
Procedures for obtaining desired cell populations, such as enrichment of certain T cell phenotypes, are one of the most expensive unit operations in an autologous T cell manufacturing process, averaging around $10K per patient in a clinical setting using the CliniMACs Plus magnetic separation technique, for example. Even after enrichment, T cell purity only reaches 90-95% and some 10% of T cells may be lost in the negative fraction (flow-through).
The standard procedure for separation of red blood cells and granulocytes from the PBMCs and lymphocytes in a harvested blood sample, such as apheresed cells, is by use of density gradient centrifugation. The typical density gradient material used for this purpose is Ficoll®, a hydrophilic polysaccharide, that separates the components in blood samples, such as whole blood or blood collected via an apheresis process or other method. A Ficoll® density gradient separates mononuclear cells, dendritic cells and lymphocytes (T, B and NK cells) which are found in the huffy coat and separated from the red blood cells, platelets, and granulocytes which are found in the pellet. However, different Ficoll® separation media, protocols, operator skill, and the like, can affect the yield, viability, and function of the cells. In addition, in some processes the cells are manipulated in a hyperosmolar Ficoll® solution followed by
resuspension in artificial media, which may have profound modifying effects on T cell function, see Mallone et al., Clinical and Experimental Immunology, 163: 33-49 (2010). Also, lymphocytes expressing high-avidity binding for autologous erythrocytes have been shown to lead to a loss of these T-rosetting cells during Ficoll® separation, see for example, Hoklandet al. Scand. J. Immunol, 11, 353-356 (1980).
In addition, apheresed cells that are further isolated, selected and/or enhanced are subjected to additional manipulations, such as centrifugation as part of wash and separation processes, density gradients, and the like. This can lead to cell damage and loss due to the repeated shear forces experienced during these processes. In addition, each time the cells are handled, whether manually or as part of an automated process, there is an increased risk of exposure and contamination of the cells. For a manufacturing facility where a high volume of samples from different donors are processed for use in autologous cell therapy applications, contamination of a processed sample with foreign donor cells is a serious risk and danger to the donor patient.
The method described herein makes use of the entire apheresed sample without further isolation, separation, and/or enrichment for specific cell populations or phenotypes. The method starts with billions of cells harvested by leukapheresis which comprise nucleated cells, such as leukocytes, including monocytes, dendritic cells, lymphocytes (T-, B-, and NK cells), and granulocytes, as well as megakaryocytes, and cells without a nucleus, such as erythrocytes and platelets. While only about 30-60% of the cells in the apheresed sample are T cells, the other supporting cells have a positive effect on the outcome of the method, contributing to the overall health of the T cells from Day 0. The genetically engineered T cells derived from these apheresed samples grew faster, had higher transduction efficiencies, and maintained a more memory -like state when they are processed along with other cells in the apheresed sample, compared to the same apheresed cells that were further enriched for specific T cell populations.
It was found that further isolation, selection and/or enrichment for any subset of the apheresed cells, such as by cell type or phenotype, was not necessary to achieve genetically engineered T cells with a high degree of purity and viability, with high transgene expression, and starting with this mixed cell population, did not impact the capability of generating cell densities well over 10 billion in a 10-day process. The resulting T cells were less differentiated and remained in a more memory -like phenotype which increases persistence and over all efficacy, as well as being more potent in killing target cells upon challenge. Starting with the apheresed cells eliminates additional separation steps such as magnetic separation or other sedimentation to isolate cells of interest, resulting in a continuous minimal manipulation operation from apheresed donor cells to harvest of genetically engineered T cells. This drastically reduces the per patient footprint inside a manufacturing facility and the time for processing the harvested cells. In addition, eliminating the need for selection or enhancement of donor cells prior to activation, results in less manipulation of the donor sample, decreases exposure to unnecessary chemicals such as Ficoll®, reduces overall cell loss, overall cost, and the possibility of damage to cells, and greatly diminished the risk of contaminating the patient sample. Autologous cell samples come from patients with grievous diseases.
There is always a risk when taking a cell sample from these patients and administering the resulting genetically engineered T cells back to the patient. Exposing the patient to additional unnecessary risks by excessive manipulation and exposure of the cells to unnecessary processing, mishandling during the intensive hands on processing, or administering contaminated cells back to the patient, is not a viable option.
The invention provides a method for producing genetically engineered autologous T cells expressing at least one protein of interest, the method comprising inoculating a closed single use bioreactor bag containing culture media with apheresed donor cells and one or more soluble T cell activators, wherein the bioreactor bag is part of a rocking bioreactor platform, culturing the cells in the closed single use bioreactor bag continuously rocking at a rate of about 2 RPM, transducing the cells in the closed single use bioreactor bag with at least one soluble viral vector comprising a polynucleotide which encodes the protein of interest continuously rocking at a rate of about 2 RPM, and expanding the cells in the closed single use bioreactor bag at a rocking rate of about 2 RPM and increasing the culture volume and rocking the rate as needed to maintain the culture until harvest.
In one embodiment the apheresed donor cells comprise cells from peripheral blood. In a related embodiment the apheresed donor cells comprise nucleated and non-nucleated cells. In one embodiment the apheresed donor cells comprise leukocytes and erythrocytes. In a related embodiment the apheresed donor cells also comprise granulocytes and/or platelets. In one embodiment the apheresis is leukapheresis. In a related embodiment the apheresed donor cells are provided in a Leukopak®.
The apheresed donor cells are not subjected to any further isolation, selection and/or enrichment for any cell population(s) or cell type(s) following apheresis, and prior to activating the apheresed donor cells.
As will be appreciated, the harvested cells may be washed to remove the plasma fraction and any apheresis buffers, and to place the harvested cells in an appropriate buffer or media for subsequent processing. Closed, automated processes are commercially available for this purpose and include Sepax C-Pro (GE Healthcare, Pittsburg, PA), Cobe 2991 cell processor (Terumo BCT, Lakewood, CO), CellSaver 5 (Haemonetics, (Boston, MA)) and the like. In one embodiment the apheresed donor cells are washed and resuspended in a culture media prior to inoculation. No additional wash steps are performed until the expanded genetically engineered autologous T cells are harvested for formulation and cryopreservation.
T cell activation is an antigen-dependent process resulting in proliferation and differentiation of naive T cells into effector cells. Activation is stimulated by primary and coactivating signals. With appropriate stimulation T cells will proliferate in vitro. T cells require two signals to become fully activated, the primary stimulation is antigen specific, from interaction of the T cell receptor with a peptide-HLA molecule on an antigen presenting cell. The second is non-antigen specific co-stimulatory signals from interaction between the membrane of the antigen presenting cell and the T cell.
As described herein, activation strength did not appear to correlate with better transduction efficiency. Bound activators did not yield high transduction rates despite providing the highest signal
strength. Soluble activators, such as the mixtures of soluble CD3, CD28, and/or CD2 antibodies, particularly the combination of soluble CD3, CD28 and CD2 antibodies, had a signal strength falling between activators bound to bags and those bound to beads, however they activated T cells with the highest expression of GFP and the engineered TCR.
One or more soluble T cell activators may be used to produce a population of activated T cells. Such T cell activators include antibodies or functional fragment thereof that target T cell stimulator and/or co-stimulatory molecules. Such T cell activators include, but are not limited to, anti-CD3 antibodies or binding fragments, anti-CD28 antibodies or binding fragments, and anti-CD2 antibodies or binding fragments, or combinations thereof. Also included are anti-human CD3 monospecific tetrameric antibody complex, an anti-human CD28 monospecific tetrameric antibody complex, and an anti-human CD2 monospecific tetrameric antibody complex. Such T cell activators are commercially available from a variety of sources including Stem Cell Technologies, Vancouver, BC CA, among others.
In one embodiment at least one T cell activator is an anti CD3 antibody or binding fragments thereof. In one embodiment the T cell activator comprises an anti CD3 antibody and an anti CD28 antibody, or binding fragments thereof. In another embodiment the T cell activator comprises at least an anti CD3 antibody, an anti CD28 antibody, and an anti CD2 antibody, or binding fragments thereof. In another embodiment the T cell activator comprises at least an anti-human CD3 monospecific tetrameric antibody complex, an anti-human CD28 monospecific tetrameric antibody complex, and an anti-human CD2 monospecific tetrameric antibody complex.
In one embodiment the concentration of at least one soluble T cell activator is at least 0.001 pg/ml to at least 10 pg/ml. In a related embodiment the concentration is at least 0.01 pg/ml to at least 10 pg/ml. In a related embodiment the concentration is at least 0.1 pg/ml to at least 10 pg/ml. In a related embodiment the concentration is at least 1 pg/ml to at least 10 pg/ml. In a related embodiment the concentration is at least 5 pg/ml to at least 10 pg/ml. In one embodiment the concentration of at least one T cell activator is at least 0.001 pg/ml to at least 1 pg/ml. In a related embodiment the concentration of at least one T cell activator is at least 0.01 pg/ml to at least 1 pg/ml. In a related embodiment the concentration of at least one T cell activator is at least 0.1 pg/ml to at least 1 pg/ml. In one embodiment the concentration of at least one T cell activator is at least 0.001 pg/ml to at least 5 pg/ml. In a related embodiment the concentration of at least one T cell activator is at least 0.01 pg/ml to at least 5 pg/ml. In a related embodiment the concentration of at least one T cell activator is at least 0.1 pg/ml to at least 5 pg/ml. In a related embodiment the concentration of at least on T cell activator is at least 1 pg/ml to at least 5 pg/ml. In one embodiment the concentration is at least O.OOlpg/ml. In one embodiment the concentration is at least O.Olpg/ml. In one embodiment the concentration is at least 0.1 pg/ml. In one embodiment the concentration is at least 1 pg/ml. In one embodiment the concentration is at least 5 pg/ml. In one embodiment the concentration is at least 10 pg/ml. In one embodiment the concentration greater than lOpg/ml.
In one embodiment the wherein the culture media comprises at least one soluble cytokine. Cytokines, such as IL-1, IL-2, IL-4, IL-5, IL-7, IL-15, and/or IL-21, may also be used as soluble T cell stimulating agents.
In one embodiment the soluble cytokine selected from IL-2, IL-7, IL-15, or IL-21. In one embodiment the soluble cytokine is IL-7 in combination with IL-15 or IL-21. Such cytokines may be used at concentrations from at least 5ng/ml to at least 30ng/ml or more. In one embodiment, the concentration of at least one cytokine is at least 5ng/ml to at least 25ng/ml. In one embodiment the concentration of at least one cytokine is at least 5ng/ml to at least 20ng.ml. In one embodiment the concentration of at least one cytokine is at least 5ng/ml to at least 15ng/ml. In one embodiment the concentration of at least one cytokine is at least 5 ng/ml to at least 10 ng/ml. In one embodiment the concentration of at least one cytokine is at least 10 ng/ml to at least 20 ng/ml. In one embodiment the concentration of at least one cytokine is at least 5ng/ml. In one embodiment the concentration of at least one cytokine is at least 10 ng/ml. In one embodiment the concentration of at least one cytokine is at least 15ng/ml. In one embodiment the concentration of at least one cytokine is at least 20 ng/ml. In one embodiment the concentration of at least one cytokine is at least 25 ng/ml. In one embodiment the concentration of at least one cytokine is at least 30ng/ml. In one embodiment the concentration of at least one cytokine is greater than 30ng/ml. Other molecules that impact T cell activation or maturation may also be included, such as a WNT pathway activator. Such activators include 4,6-disubstituted pyrrolopyrimidine TWS119, an inhibitor of the serine/threonine kinase glycogen- synthase-kinase-3 b (Gsk-3 ), (Stemcell Technologies). In one embodiment the concentration of TWS119 is at least 5 mM to at least 20 pM or more. In one embodiment the concentration of TWS119 is at least 5 pM to at least 15 pM. In one embodiment the concentration of TWS119 is at least 5 pM to at least 10 pM. In one embodiment the concentration of TWS119 is at least 10 pM to at least 20 pM. In one embodiment the concentration of TWS119 is at least 5 pM. In one embodiment the concentration of TWS119 is at least 10 pM. In one embodiment the concentration of TWS119 is at least 15 pM. In one embodiment the concentration of TWS119 is at least 20 pM. In one embodiment the concentration of TWS119 is greater than 20 pM. In one embodiment the culture media comprises a mixture of soluble TWS117, IL-7, and IL- 21
In one embodiment least one soluble cytokine is IL-2. In one embodiment the IL-2 is at a concentration of about 250 IU/ml to about 350 IU/ml. In one embodiment the soluble cytokine is IL-2 at a concentration of about 250 IU/ml to 300 IU/ml. In one embodiment the soluble cytokine is IL-2 at a concentration of about 300 IU/ml to 350 IU/ml. In one embodiment the soluble cytokine is IL-2 at a concentration of about 250 IU/ml, 300 IU/ml, or 350 IU/ml. In one embodiment the soluble cytokine is IL- 2 at a concentration of about 250 IU/ml. In one embodiment the soluble cytokine is IL-2 at a concentration of about 300 IU/ml. In one embodiment the soluble cytokine is IL-2 at a concentration of about 350 IU/ml.
During antigen stimulation, T cells shift to a glycolytic metabolism to sustain effector function. This happens in the first few days after adding activators to the cells. Glycolysis inhibitors can be added
with the activators to inhibit glycolysis metabolism during the activation and transduction steps, which can contribute to generation of T cells with less differentiated phenotypes, enhanced transduction efficiency, and/or enhanced T cell expression. As described herein, the engineered T cells derived from 2-deoxy-D- glucose (2-DG)-inhibited T cells produced more Tscm and Tcm compared with the T cells derived from the media without 2-DG. The inhibitor can be kept in the culture media until harvest or removed at any point to restore glycolysis and support T cell expansion. In one embodiment the culture media also comprises a soluble glycolysis inhibitor. In a related embodiment the soluble glycolysis inhibitor is 2- deoxy-D-glucose (2-DG). In one embodiment the concentration of 2-DG is about 1 mM to about 3mM. In a related embodiment the concentration of 2-DG is about ImM to about 2mM. In a related embodiment the concentration of 2-DG is about 2mM to about 3mM. In one embodiment the concentration of 2-DG is about ImM or less. In one embodiment the concentration is about 2mM. In one embodiment the concentration of 2-DG is about 3mM or more.
Procedures for producing engineered T cells comprise many unit operations such as cell isolation, selection and/or enrichment of the harvested donor sample for a particular cell type or phenotype, activation, transduction, expansion, harvest, formulation, and cryopreservation. During each of these steps, multiple vessels or processes may be used to perform each operation. For example, to obtain a desired cell type or phenotype, one or more closed vessels and/or processes may be used to perform steps such as washes, magnetic-antibody labeling, performing selection or enrichments procedures, centrifugation/sedimentation, and concentration of the isolated, selected, or enriched cells. Much use is made of bound activators for activation and/or bound agents to enhance transduction, whether they are coated on plates, or bags or bound to beads or other supports. Once the stimulation or transduction using these bound activators is complete, the cells must be removed, washed, and transferred to new vessels. Multiple vessels may be used during expansion to accommodate increased demand for nutrients and increasing culture volume. Switches between different types of vessels associated with these steps is time-consuming and costly and may expose the cells to damage, loss and contamination.
As described herein, the invention provides a closed continuous operation from inoculation of apheresed donor cells all the way through to the harvest of expanded genetically engineered T cells. All steps, including activation, transduction, and expansion, take place in a single closed bioreactor system that is constantly rocked at a speed of at least 2RPM. This not only minimizes manual manipulation of donor material, reducing risk of contamination and cell loss, it allows for automated feeding and culture manipulation. Additional equipment, such as incubators and separate vessels for activation and/or transduction, are not necessary to process the donor’s cells which drastically reduces the risk of contamination and cells loss, but also reduced the cost in materials/reagents and FTE time, and the per patient footprint inside a manufacturing facility.
As described herein, activation, transduction, and expansion in a continuously rocking bioreactor that makes use of soluble components in a culture media optimized for T cell growth, resulted in a high- density production of engineered autologous T cells from washed apheresed donor cells. Use of soluble
components such as T cell activators, stimulators, and metabolic pathway inhibitors, allowed for a continuous flow between the various steps in the manufacture of the autologous engineered T cells and produced engineered T cells at a desired phenotype and transgene expression. Rocking during this process also ensured a sufficient mass transfer of oxygen and nutrients to support high-density cultures in contrast to static cultures which must be grown at low cell density (< 2E6 cells/ml) due to limitation of the culture media under static conditions. While the rocking bioreactors and commonly used G-Rex® gas permeable culture systems both have efficient oxygen transport, the G-Rex® systems lacks the convection flow that transfers nutrients to cells in a timely manner. Also, using the rocking bioreactor system allows for perfusion of fresh media which enable very high cell densities, up to 50E6 cells/ml in some cases.
Activation, transduction, and expansion of autologous donor apheresed cells comprising leukocytes and erythrocytes, was carried out in a continuous closed system within a single bioreactor bag that was rocked continuously. Bioreactor bags, such as Cellbag™ bioreactor bags (GE Healthcare) are used as part of rocking bioreactor platforms such as Wave or Xuri Cell Expansion systems (GE Healthcare), and in addition to operating as a bioreactor also have the capability of rocking at various speeds and angles which allows efficient mass transfer of oxygen and nutrients without introducing too much shear stress to T cells. Such bioreactor bags are typically equipped with perfusion fdters to fdter incoming culture media, ports and lines for adding culture media and other components, withdrawing spent media and samples, all within a sterile controlled environment. The bags are also equipped to connect with controls on the rocking platform system that automatically measure and control culture parameters such as temperature, C02, 02, pH and metabolic and media parameters such as glucose and lactate, as well as controlling gas and media flow. The bags allow for automated feeding, be it bolus, fed batch, fed batch/perfusion, and/or semi- or continuous perfusion. In addition to reducing the amount of manual manipulation of cells, culturing the cells in a closed bioreactor system allows for greater capacity and improvement to the yield and culture density of the engineered T cells.
Production of engineered autologous T cells for cell therapy indications typically relies on static cultures that make use of gas permeable vessels can require extensive manual manipulation, exposing the cultures and the equipment to contamination risk as well as limiting nutrient flow to cells. Static, gas permeable vessels, such as bags, flasks, and plates, are widely used in autologous T cell processes that involve a transduction step to produce genetically engineered T cells. Examples of such static gas permeable cell culture bags currently used include Permalife Cell Culture Bags, Origin Biomedical, Austin Texas, MACS GMP Cell Differentiation Bags, Miltenyi Biotech, Cambridge, MA), Rapid Expansion Flask (G-Rex) bioreactor, other G-Rex® vessels Wilson-Wolf Manufacturing. The vessels require an incubator or other climate-controlled chamber to maintain desired temperatures and are gas permeable to allow passive diffusion of 02 from the ambient incubator environment and C02 from the media. The vessels require manual manipulation to move them to and from processing equipment, incubators, or biosafety cabinets, and the like that are necessary for maintaining the cultures. In addition, the vessels require
constant connecting and reconnecting to processing equipment, syringes, pumps, chambers, and other vessels and devices to maintain the cultures. The manual processing increases the risk of contamination to the cultures. In addition, Permalife Cell Culture bags are only designed for low density T cell expansion (<2E6 cells/ml) and will require extremely large volumes to supply at the high-dosages required for T cell therapy. G-rex®, on the other hand, could expand T cells in a relatively high density (-10E6 cells/ml) but are challenged with any manipulation of expansion parameters. These two vessels are also not equipped with control systems and data recording ability to support a more advanced and digital manufacturing operation.
The inventive method provides inoculating a closed single use bioreactor bag containing culture media with apheresed donor cells and one or more soluble T cell activators, wherein the bioreactor bag is part of a rocking bioreactor platform. The volume of culture media in the bioreactor bag at the time of inoculation can be any predetermined volume. In one embodiment the volume of culture media is at least the minimal volume of the bioreactor bag. In one embodiment the second volume of culture media is at least 300 ml. In one embodiment the volume of the culture media 400 ml or more. In one embodiment the volume of culture media is about 300 ml to about 400 ml. In one embodiment the volume of the culture media is about 325 ml to about 400 ml. In one embodiment the volume of the culture media is about 350 ml to about 400 ml. In one embodiment the volume of the culture media is about 375 ml to about 400 ml. In one embodiment the volume of culture media is about 300 ml, about 325 ml, about 350 ml, about 375 ml, or about 400 ml. In one embodiment the volume of culture media is about 300 ml. In one embodiment the volume of culture media is about 325 ml. In one embodiment the volume of culture media is about 350 ml. In one embodiment the volume of culture media about 375 ml. In one embodiment the volume of culture media is about 400 ml. In one embodiment the volume of culture media is about 400 ml or more.
T cells require cell-cell contact to activate and survive. An insufficient concentration of cells during activation could reduce cell-cell contact to a level associated with poor activation. The apheresed donor cells comprise nucleated and non-nucleated cells. The number of nucleated cells in the apheresed donor sample can be determined by any known method, including the use of automated systems such as a NC- 200™ Automated Cell Counter (ChemMetec, Denmark). In one embodiment the apheresed donor cells comprise a sufficient number of nucleated cells for activation in the bioreactor bag at a rocking speed of 2RPM. In one embodiment the apheresed donor cells comprise about 1.0E9 to 1.3E9 nucleated cells. In a related embodiment the apheresed donor cells comprise about 1.1E9 to about 1.2E9 nucleated cells. In a related embodiment the apheresed donor cells comprise about 1.2E9 to about 1.3E9 nucleated cells. In a related embodiment the apheresed donor cells comprise about 1.2E9 to about 1.25E9 nucleated cells. In a related embodiment the apheresed donor cells comprise about 1.0E9 nucleated cells. In a related embodiment the apheresed donor cells comprise about 1.1E9 nucleated cells. In a related embodiment the apheresed donor cells comprise about 1.2E9 nucleated cells. In a related embodiment the apheresed donor cells comprise about 1.25E9 nucleated cells. In a related embodiment the apheresed donor cells comprise about 1.3E9 nucleated cells. In a related embodiment the apheresed donor cells comprise about 1.0E6
nucleated cells, about 1.1E9 nucleated cells, about 1.2E9 nucleated cells, about 1.25E9 nucleated cells, or about 1.3E9 nucleated cells.
In one embodiment the invention provides inoculating a closed single use bioreactor bag containing culture media with apheresed donor cells at a cell density of about 1E6 to about 5E6 nucleated cells/ml. In a related embodiment the cell density of about 2E6 to about 4E6 nucleated cells/ml. In one embodiment the cell density is about 3E6 to about 4E6 nucleated cells/ml. In one embodiment the cell density is about 3E6 to about 3.75E6 nucleated cells/ml. In one embodiment the cell density is about 3E6 to about 3.5E6 nucleated cells/ml. In one embodiment the cell density is about 3E6 to about 3.35E6 nucleated cells/ml. In one embodiment the cell density is about 2E6 to about 3E6 nucleated cells/ml. In one embodiment the cell density is about 2E6 nucleated cells/ml, about 3E6 nucleated cells/ml, about 3.25E6 nucleated cells/ml, about 3.75E6 nucleated cells/ml, or about 4E6 nucleated cells/ml. In one embodiment the cell density is about 2E6 nucleated cells/ml. In one embodiment the cell density is about 3E6 nucleated cells/ml. In one embodiment the cell density is about 3.25E6 nucleated cells/ml. In one embodiment the cell density is about 3.75E6 nucleated cells/ ml. In one embodiment the cell density is about 4E6 nucleated cells/ml. In one embodiment the cell density is about 3E6 nucleated cells/ml to 4E6 nucleated cells/ml in about 300 ml culture media containing a soluble cytokine.
The during activation cells can be cultured at a predetermined temperature. In one embodiment, the cells are cultured at 34-39°C. In one embodiment, the cells are cultured at 34-35°C. In one embodiment, the cells are cultured at 35-37°C. In one embodiment, the cells are cultured at 35-36°C. In one embodiment, the cells are cultured at 36-37°C. In one embodiment, the cells are cultured at 34°C, 35°C, 36°C, or 37°C. In one embodiment, the cells are cultured at 34°C. In one embodiment, the cells are cultured at 35°C. In one embodiment, the cells are cultured at 36°C. In one embodiment, the cells are cultured at performed at 37°C.
The during activation cells can be cultured for a predetermined time. In one embodiment, the cells are cultured for at least 12 hours. In one embodiment, the cells are cultured for at least 24 hours. In one embodiment the cells are cultured for at least 12 to at least 24 hours. In one embodiment the cells are cultured for at least 12 to at least 20 hours. In one embodiment the cells are cultured for at least 12 to at least 18 hours. In one embodiment the cells are cultured for at least 12 to at least 16 hours. In one embodiment the cells are cultured for at least 12 to at least 14 hours. In one embodiment the cells are cultured for at least 14 to at least 24 hours. In one embodiment the cells are cultured for at least 14 to at least 20 hours. On one embodiment the cells are cultured for at least 14 to at least 18 hours. On one embodiment the cells are cultured for at least 14 to at least 16 hours. On one embodiment the cells are cultured for at least 16 to at least 24 hours. On one embodiment the cells are cultured for at least 16 to at least 20 hours. In one embodiment the cells are cultured for at least 16 to at least 18 hours. On one embodiment the cells are cultured for at least 18 to at least 24 hours. In one embodiment the cells are cultured for at least 18 to 20 hours. In one embodiment the cells are cultured for at least 20 to at least 24 hours. In one embodiment the cells are cultured for at least 12 hours. In one embodiment the cells are
cultured for at least 13 hours. In one embodiment the cells are cultured for at least 14 horns. In one embodiment the cells are cultured for at least 15 hours. In one embodiment the cells are cultured for at least 16 hours. In one embodiment the cells are cultured for at least 17 hours. In one embodiment the cells are cultured for at least 18 hours. In one embodiment the cells are cultured for at least 19 hours. In one embodiment the cells are cultured for at least 20 hours. In one embodiment the cells are cultured for at least 21 hours. In one embodiment the cells are cultured for at least 22 hours. In one embodiment the cells are cultured for at least 23 hours. In one embodiment the cells are cultured for at least 24 hours.
In one embodiment of the invention, at least one soluble T-cell activator is bound to at least one donor cell at the time of inoculation. In one embodiment the apheresed donor cells are incubated with one or more soluble T cell activators prior to inoculating into the bioreactor bag. In one embodiment the incubation is for a sufficient time to allow for saturation of binding of one or more soluble T cell activators to the apheresed donor cells prior to inoculation. In one embodiment the apheresed donor cells are incubated with one or more T cell activators for at least 30 minutes or more. In one embodiment the apheresed donor cells are incubated with one or more T cell activators for at least 30 minutes to at least 2 hours or more. In a related embodiment the apheresed donor cells are incubated with one or more T cell activators for at least 1 hour to at least 2 hours. In one embodiment the incubation is at least 30 minutes. In one embodiment the incubation is about 1 hour. In one embodiment the incubation is about 2 hours.
In one embodiment the apheresed donor cells and one or more soluble T cell activators are incubated in a transfer bag. A minimal amount of culture media, enough to suspend the cells and the soluble T cell activator and allow for binding of the activator to the nucleated cells, is used, preferably enough to keep the total volume of cells. In one embodiment the volume of culture media in the transfer bag is about 5 ml to about 50 ml. In one embodiment of the invention, the initial volume of culture media comprising a soluble cytokine and one or more T cell activators is about 5 ml to about 40 ml. In one embodiment of the invention, the initial volume of culture media comprising a soluble cytokine and one or more T cell activators is about 5 ml to about 30 ml. In one embodiment of the invention, the initial volume of culture media comprising a soluble cytokine and one or more T cell activators is about 5 ml to about 20 ml. In one embodiment of the invention, the initial volume of culture media comprising a soluble cytokine and one or more T cell activators is about 5 ml to about 15 ml. In one embodiment of the invention, the initial volume of culture media comprising a soluble cytokine and one or more T cell activators is about 5 ml to about 14 ml. In one embodiment of the invention, the initial volume of culture media comprising a soluble cytokine and one or more T cell activators is about 5 ml to about 13 ml. In one embodiment of the invention, the initial volume of culture media comprising a soluble cytokine and one or more T cell activators is about 5 ml to about 12 ml. In one embodiment of the invention, the initial volume of culture media comprising a soluble cytokine and one or more T cell activators is about 5 ml to about 11 ml. In one embodiment of the invention, the initial volume of culture media comprising a soluble cytokine and one or more T cell activators is about 5 ml to about 10 ml. In one embodiment of the invention, the initial volume of culture media comprising a soluble cytokine and one or more T cell activators is about 5 ml to about 9 ml. In one
embodiment of the invention, the initial volume of culture media comprising a soluble cytokine and one or more T cell activators is about 5 ml to about 8 ml. In one embodiment of the invention, the initial volume of culture media comprising a soluble cytokine and one or more T cell activators is about 5 ml to about 7 ml. In one embodiment of the invention, the initial volume of culture media comprising a soluble cytokine and one or more T cell activators is about 5 ml to about 6 ml. In one embodiment of the invention, the initial volume of culture media comprising a soluble cytokine and one or more T cell activators is about 8 ml, about 6 ml, about 7 ml, about 8 ml, about 9 ml, about 10 ml, about 15 ml, about 20 ml, about 30 ml, about 40 ml, or about 50 ml.
Transduction refers to the process whereby foreign DNA is introduced into a cell via viral vector. See Jones et al., (1998). Genetics: principles and analysis. Boston: Jones & Bartlett Publ. As used herein, “vector” means any molecule or entity such as a viral a vector, that is useful for transformation of a host cell, such as a T cell, and contain nucleic acid sequences that direct and/or control (in conjunction with the cell) expression of one or more heterologous coding regions operatively linked thereto. An expression construct may include, but is not limited to, sequences that affect or control transcription, translation, and, if introns are present, affect RNA splicing of a coding region operably linked thereto. One or more vectors are then inserted into the cell for amplification and/or polypeptide expression. The transformation of an expression vector into a selected cell may be accomplished through viral transformation. Viral transformed T cells can be obtained by transducing cells with a viral vector comprising a polynucleotide which encodes the protein of interest. Viral vectors include retroviral vectors, murine leukemia virus vectors, SFG vectors, adenoviral vectors, lentiviral vectors, adeno-associated virus (AAV) vectors, Herpes virus vectors, and vaccinia virus vectors.
The invention provides transducing the cells in the closed single use bioreactor bag with at least one viral vector comprising a polynucleotide which encodes the protein of interest while continuously rocking at a rate of 2 RPM. The continuous rocking rate of 2RPM allowed for sufficient cell-cell contact, necessary for successful transformation. In one embodiment the culture is rocked at a rate of 2 RMP at a 2° angle.
In one embodiment, the viral vector is a retroviral vector. Retroviral vectors, such as lentivirus vectors, persist in the nucleus as integrated provirus and reproduce with cell division. In one embodiment the viral vector is a lentiviral vector.
In one embodiment the cells can be engineered using one or more viral vectors comprising one or more polynucleotide sequences encoding one or more proteins of interest. In one embodiment the protein of interest is cell surface receptor. In one embodiment the cell surface receptor is a chimeric antigen receptor or a T cell receptor. In one embodiment the cell surface receptor recognizes an antigenic target on the surface of a target cell.
In one embodiment the lentiviral vector is added at a multiplicity of infection (MOI) of 0.25-10. In one embodiment the lentiviral vector is added at a MOI of 0.25-5. In one embodiment the lentiviral vector is added at a MOI of 0.25-2. In one embodiment the lentiviral vector is added at a MOI of 0.25-1. In one embodiment the lentiviral vector is added at a MOI of 0.25-0.5. In one embodiment the lentiviral vector is added at a MOI of 0.5-10. In one embodiment the lentiviral vector is added at a MOI of 0.5-5. In one embodiment the lentiviral vector is added at a MOI of 0.5-2. In one embodiment the lentiviral vector is added at a MOI of 0.5-1. In one embodiment the lentiviral vector is added at a MOI of 1-10. In one embodiment the lentiviral vector is added at a MOI of 1-5. In one embodiment the lentiviral vector is added at a MOI of 1-2. In one embodiment the lentiviral vector is added at a MOI of 2-10. In one embodiment the lentiviral vector is added at a MOI of 2-5. In one embodiment the lentiviral vector is added at a MOI of 5-10. In one embodiment the lentiviral vector is added at a MOI of 0.25, 0.5, 1, 2, 5, or 10. In one embodiment the lentiviral vector is added at a MOI of 10. In one embodiment the lentiviral vector is added at a MOI of 5. In one embodiment the lentiviral vector is added at a MOI of 2. In one embodiment the lentiviral vector is added at a MOI of 1. In one embodiment the lentiviral vector is added at a MOI of 0.5. In one embodiment the lentiviral vector is added at a MOI of 0.25.
The cells can be transduced at a predetermined temperature. In one embodiment, the cells are transduced at 34-39°C. In one embodiment, the cells are transduced at 34-35°C. In one embodiment, the cells are transduced at 35-37°C. In one embodiment, the cells are transduced at 35-36°C. In one embodiment, the cells are transduced at 36-37°C. In one embodiment, the cells are transduced at 34°C, 35°C, 36°C, or 37°C. In one embodiment, the cells are transduced at 34°C. In one embodiment, the cells are transduced at 35°C. In one embodiment, the cells are transduced at 36°C. In one embodiment, the cells are transduced at performed at 37°C.
The cells can be transduced for a predetermined time. In one embodiment, the cells are transduced for at least 12 hours. In one embodiment, the cells are transduced for at least 24 hours. In one embodiment the cells are transduced for at least 12 to at least 24 hours. In one embodiment the cells are transduced for at least 12 to at least 20 hours. In one embodiment the cells are transduced for at least 12 to at least 18 hours. In one embodiment the cells are transduced for at least 12 to at least 16 hours. In one embodiment the cells are transduced for at least 12 to at least 14 hours. In one embodiment the cells are transduced for at least 14 to at least 24 hours. In one embodiment the cells are transduced for at least 14 to at least 20 hours. On one embodiment the cells are transduced for at least 14 to at least 18 hours. On one embodiment the cells are transduced for at least 14 to at least 16 hours. On one embodiment the cells are transduced for at least 16 to at least 24 hours. On one embodiment the cells are transduced for at least 16 to at least 20 hours. In one embodiment the cells are transduced for at least 16 to at least 18 hours. On one embodiment the cells are transduced for at least 18 to at least 24 hours. In one embodiment the cells are transduced for at least 18 to 20 hours. In one embodiment the cells are transduced for at least 20 to at least 24 hours. In one embodiment the cells are transduced for at least 12 hours. In one embodiment the cells are transduced
for at least 13 hours. In one embodiment the cells are transduced for at least 14 hours. In one embodiment the cells are transduced for at least 15 hours. In one embodiment the cells are transduced for at least 16 hours. In one embodiment the cells are transduced for at least 17 hours. In one embodiment the cells are transduced for at least 18 hours. In one embodiment the cells are transduced for at least 19 hours. In one embodiment the cells are transduced for at least 20 hours. In one embodiment the cells are transduced for at least 21 hours. In one embodiment the cells are transduced for at least 22 hours. In one embodiment the cells are transduced for at least 23 hours. In one embodiment the cells are transduced for at least 24 hours.
As described herein, transduction was performed using a rocking bioreactor equipped with a single use bioreactor bag at a rocking rate of 2 RPM, in particular, a rocking rate of 2 RPM at an angle of 2°. One or more viral vectors comprising polynucleotides encoding proteins of interest may be directly inoculated into the culture in the bioreactor bag while the bag is rocking. Use of bags impermeable to gas such as those as used on rocking bioreactors has not been recommended for use during transduction. “Vessels that are impermeable to gas, such as disposable bioreactors that are designed to fit rocking motion bioreactors, are not ideal for transduction of cells via viral vectors. Therefore, transduction is currently carried out in static cell culture bags or planar vessels.”, see Farid and Jenkins, Bioprocesses for Cell Therapies, Chapter 44, Biopharmeceutical Processing: Development, Design and Implementation of Manufacturing Processes, Eds. Jagschies et al., Elsevier, page 914, 2018.
However, as described herein, compared to cells transduced in static gas permeable vessels, the cells transduced in disposable bioreactors bags designed to be part of rocking motion bioreactors, had a greater transduction efficiency, were less differentiated, more memory -cell like, and had greater potency in killing target cells than those cells transduced in a static gas permeable bag or in a static G-Rex® gas permeable system.
In one embodiment, following transduction, half of the culture media is removed from the bioreactor bag and replaced with an equal volume of fresh culture media and rocked at a rate of 2 RPM. In one embodiment the culture is rocked at a rate of 2 RMP at a 2° angle.
The cells can be cultured at a predetermined temperature. In one embodiment, the cells are cultured at 34-39°C. In one embodiment, the cells are cultured at 34-35°C. In one embodiment, the cells are cultured at 35-37°C. In one embodiment, the cells are cultured at 35-36°C. In one embodiment, the cells are cultured at 36-37°C. In one embodiment, the cells are cultured at 34°C, 35°C, 36°C, or 37°C. In one embodiment, the cells are cultured at 34°C. In one embodiment, the cells are cultured at 35°C. In one embodiment, the cells are cultured at 36°C. In one embodiment, the cells are cultured at performed at 37°C.
The cells can be cultured for a predetermined time. In one embodiment, the cells are cultured for at least 12 hours. In one embodiment, the cells are cultured for at least 24 hours. In one embodiment the cells are cultured for at least 12 to at least 24 hours. In one embodiment the cells are cultured for at least 12 to at least 20 hours. In one embodiment the cells are cultured for at least 12 to at least 18 hours. In one embodiment the cells are cultured for at least 12 to at least 16 hours. In one embodiment the cells are
cultured for at least 12 to at least 14 hours. In one embodiment the cells are cultured for at least 14 to at least 24 horns. In one embodiment the cells are cultured for at least 14 to at least 20 hours. On one embodiment the cells are cultured for at least 14 to at least 18 hours. On one embodiment the cells are cultured for at least 14 to at least 16 hours. On one embodiment the cells are cultured for at least 16 to at least 24 hours. On one embodiment the cells are cultured for at least 16 to at least 20 hours. In one embodiment the cells are cultured for at least 16 to at least 18 hours. On one embodiment the cells are cultured for at least 18 to at least 24 hours. In one embodiment the cells are cultured for at least 18 to 20 hours. In one embodiment the cells are cultured for at least 20 to at least 24 hours. In one embodiment the cells are cultured for at least 12 hours. In one embodiment the cells are cultured for at least 13 hours. In one embodiment the cells are cultured for at least 14 hours. In one embodiment the cells are cultured for at least 15 hours. In one embodiment the cells are cultured for at least 16 hours. In one embodiment the cells are cultured for at least 17 hours. In one embodiment the cells are cultured for at least 18 hours. In one embodiment the cells are cultured for at least 19 hours. In one embodiment the cells are cultured for at least 20 hours. In one embodiment the cells are cultured for at least 21 hours. In one embodiment the cells are cultured for at least 22 hours. In one embodiment the cells are cultured for at least 23 hours. In one embodiment the cells are cultured for at least 24 hours.
The invention provides expanding the cells in the closed single use bioreactor bag at a rocking rate of about 2 RPM and increasing the culture volume and rocking the rate as needed to maintain the culture until harvest. T cells require cell-cell contact to survive. Less than 2E6 cells/ml can deprive cell-cell contact, increase cell stress, and/or decrease ability to overcome bioreactor agitation and to proliferate. Scale-up to 4E6 cells/ml or more allows for timely increases in the culture volume, which also simplifies the feeding process. Stepwise increased in culture volume allow for scale up of the culture to 1 liter in a timely manner, with rocking speed/angle corresponding to increases in volume to allow for a steady amount of dissolve oxygen in the system to facilitate cell expansion. During activation, T cells consume and release large amounts of glucose and lactate. High levels of lactate appear to be detrimental for T cell activation and expansion. As a result, cell media exchange is not a parameter corresponding to cell density in the early phase of activation and transduction as the cells are not expanding much. During activation/transduction, lactate level is the critical culture parameter and sufficient turnover of media is a critical for T cell activation and expansion. Semi-continuous media exchange is used to control metabolite level in the culture media.
T cells can reach a higher density when cultured in a rocking bioreactor platform than in static gas permeable vessel system. Final yield for the process described herein, was between 15 million to 35 billion cells in a 1L bioreactor in 10-14 days. One bioreactor is sufficient to support one patient. To achieve the same 10 billion engineered T cells as produced in a single liter produced by the inventive method would require ~20 permeable bags (250ml) or a 4L G®-rex bioreactor. The cell yield of the inventive method is higher than that of other common process in field.
In one embodiment, as the cells expand the volume of the culture media is incrementally increased to maintain a cell density of at least 2E6 nucleated cells/ml. In one embodiment the cells expand the volume of the culture media in bioreactor is incrementally increased to 1 liter during expansion to maintain a cell density of at least 4E6 nucleated cells/ml. In one embodiment the cell density during expansion is at least 2E6 cells/ml or higher. In one embodiment the cell density is about 2E6 cells/ml to about 3.75E6 cells/ml. In one embodiment the cell density is about 2E6 cells/ml to about 3.50E6 cells/ml. In one embodiment the cell density is about 2E6 cells/ml to about 3.25E6 cells/ml. In one embodiment the cell density is about 2E6 cells/ml to about 3.00E6 cells/ml. In one embodiment the cell density is about 2E6 cells/ml to about 2.75E6 cells/ml. In one embodiment the cell density is about 2E6 cells/ml to about 2.50E6 cells/ml. In one embodiment the cell density is about 2E6 cells/ml to about 2.25E6 cells/ml. In one embodiment the cell density is about 2.25E6 cells/ml to about 4.0E6 cells/ml. In one embodiment the cell density is about 2.25E6 cells/ml to about 3.75E6 cells/ml. In one embodiment the cell density is about 2.25E6 cells/ml to about 3.50E6 cells/ml. In one embodiment the cell density is about 2.25E6 cells/ml to about 3.25E6 cells/ml. In one embodiment the cell density is about 2.25E6 cells/ml to about 3.0E6 cells/ml. In one embodiment the cell density is about 2.25E6 cells/ml to about 2.75E6 cells/ml. In one embodiment the cell density is about 2.25E6 cells/ml to about 2.50E6 cells/ml. In one embodiment the cell density is about 2.50E6 cells/ml to about 4.0E6 cells/ml. In one embodiment the cell density is about 2.50E6 cells/ml to about 3.75E6 cells/ml. In one embodiment the cell density is about 2.50E6 cells/ml to about 3.50E6 cells/ml. In one embodiment the cell density is about 2.50E6 cells/ml to about 3.25E6 cells/ml. In one embodiment the cell density is about 2.50E6 cells/ml to about 3.00E6 cells/ml. In one embodiment the cell density is about 2.50E6 cells/ml to about 2.75E6 cells/ml. In one embodiment the cell density is about 2.50E6 cells/ml to about 2.50E6 cells/ml. In one embodiment the cell density is about 2.50E6 cells/ml to about 2.75E6 cells/ml. In one embodiment the cell density is about 2.75E6 cells/ml to about 4.0E6 cells/ml. In one embodiment the cell density is about 2.75E6 cells/ml to about 3.75E6 cells/ml. In one embodiment the cell density is about 2.75E6 cells/ml to about 3.50E6 cells/ml. In one embodiment the cell density is about 2.75E6 cells/ml to about 3.25E6 cells/ml. In one embodiment the cell density is about 2.75E6 cells/ml to about 3.00E6 cells/ml. In one embodiment the cell density is about 2.75E6 cells/ml to about 2.75E6 cells/ml. In one embodiment the cell density is about 2.75E6 cells/ml to about 2.50E6 cells/ml. In one embodiment the cell density is about 3.0E6 cells/ml to about 4.0E6 cells/ml. In one embodiment the cell density is about 3.0E6 cells/ml to about 3.75E6 cells/ml. In one embodiment the cell density is about 3.0E6 cells/ml to about 3.50E6 cells/ml. In one embodiment the cell density is about 3.0E6 cells/ml to about 3.25E6 cells/ml. In one embodiment the cell density is about 3.25E6 cells/ml to about 4.0E6 cells/ml. In one embodiment the cell density is about 3.25E6 cells/ml to about 3.75E6 cells/ml. In one embodiment the cell density is about 3.25E6 cells/ml to about 4.0E6 cells/ml. In one embodiment the cell density is about 3.50E6 cells/ml to about 4.0E6 cells/ml. In one embodiment the cell density is about 3.50E6 cells/ml to about 3.75E6 cells/ml. In one embodiment the cell density is about 3.75E6 cells/ml to about 4.0E6 cells/ml.
In one embodiment, during expansion, fresh culture media is added to the bioreactor by a combination of fed batch/perfusion feeding and/or by perfusion. In one embodiment, fresh culture media is added by fed batch/perfusion until the culture reaches a volume of at least 1 liter, then the culture is switched to perfusion until harvest. In one embodiment the culture is perfused throughout expansion until harvest. In one embodiment during expansion the perfusion rate is at least one bioreactor bag volume per day. In one embodiment the perfusion rate is less than one bioreactor bag volume per day. In one embodiment the perfusion rate is greater than one bioreactor bag volume per day.
In one embodiment the volume of the culture media in bioreactor is incrementally increased to 1000 ml during expansion to maintain a cell density of about 2E6 to about 4E6 nucleated cells/ml. In one embodiment the bioreactor volume is increased from at least 200 ml to at least 1000 ml. In one embodiment the bioreactor volume is increased from at least 300 ml to at least 1000 ml. In one embodiment the bioreactor volume is increased from at least 400 ml to at least 1000 ml. In one embodiment the bioreactor volume is increased from at least 500 ml to at least 1000 ml. In one embodiment the bioreactor volume is increased from at least 600 ml to at least 1000 ml. In one embodiment the bioreactor volume is increased from at least 700 ml to at least 1000 ml. In one embodiment the bioreactor volume is increased from at least 800 ml to at least 1000 ml. In one embodiment the bioreactor volume is increased from at least 900 ml to at least 1000 ml. In one embodiment the bioreactor volume is increased from at least 200 ml to at least 900 ml. In one embodiment the bioreactor volume is increased from at least 300 ml to at least 900 ml. In one embodiment the bioreactor volume is increased from at least 400 ml to at least 900 ml. In one embodiment the bioreactor volume is increased from at least 500 ml to at least 900 ml. In one embodiment the bioreactor volume is increased from at least 600 ml to at least 900 ml. In one embodiment the bioreactor volume is increased from at least 700 ml to at least 900 ml. In one embodiment the bioreactor volume is increased from at least 800 ml to at least 900 ml. In one embodiment the bioreactor volume is increased from at least 200 ml to at least 800 ml. In one embodiment the bioreactor volume is increased from at least 300 ml to at least 800 ml. In one embodiment the bioreactor volume is increased from at least 400 ml to at least 800 ml. In one embodiment the bioreactor volume is increased from at least 500 ml to at least 800 ml. In one embodiment the bioreactor volume is increased from at least 700 ml to at least 800 ml. In one embodiment the bioreactor volume is increased from at least 700 ml to at least 800 ml. In one embodiment the bioreactor volume is increased from at least 300 ml to at least 700 ml. In one embodiment the bioreactor volume is increased from at least 200 ml to at least 800 ml. In one embodiment the bioreactor volume is increased from at least 400 ml to at least 800 ml. In one embodiment the bioreactor volume is increased from at least 500 ml to at least 800 ml. In one embodiment the bioreactor volume is increased from at least 600 ml to at least 800 ml. In one embodiment the bioreactor volume is increased from at least 700 ml to at least 800 ml. In one embodiment the bioreactor volume is increased from at least 200 ml to at least 700 ml. In one embodiment the bioreactor volume is increased from at least 200 ml to at least 700 ml. In one embodiment the bioreactor volume is increased from at least 300 ml to at least 700 ml. In one embodiment
the bioreactor volume is increased from at least 400 ml to at least 700 ml. In one embodiment the bioreactor volume is increased from at least 500 ml to at least 700 ml. In one embodiment the bioreactor volume is increased from at least 600 ml to at least 700 ml. In one embodiment the bioreactor volume is increased from at least 200 ml to at least 600 ml. In one embodiment the bioreactor volume is increased from at least 300 ml to at least 600 ml. In one embodiment the bioreactor volume is increased from at least 400 ml to at least 600 ml. In one embodiment the bioreactor volume is increased from at least 500 ml to at least 600 ml. In one embodiment the bioreactor volume is increased from at least 200 ml to at least 500 ml. In one embodiment the bioreactor volume is increased from at least 300 ml to at least 500 ml. In one embodiment the bioreactor volume is increased from at least 400 ml to at least 500 ml. In one embodiment the bioreactor volume is increased from at least 200 ml to at least 400 ml. In one embodiment the bioreactor volume is increased from at least 300 ml to at least 400 ml. In one embodiment the bioreactor volume is at least 200 ml, 250 ml, 300 ml, 350 ml, 400 ml, 450 ml, at least 500 ml, at least 550 ml, at least 600 ml, at least 650 ml, at least 700 ml, at least 750 ml, at least 800 ml, at least 850 ml, at least 900 ml, at least 950 ml, at least 1000 ml, or above 1000 ml. In one embodiment the bioreactor volume is at least 200 ml. In one embodiment the bioreactor volume is at least 300 ml. In one embodiment the bioreactor volume is at least 400 ml. In one embodiment the bioreactor volume is at least 500 ml. In one embodiment the bioreactor volume is at least 600 ml. In one embodiment the bioreactor volume is at least 700 ml. In one embodiment the bioreactor volume is at least 800 ml. In one embodiment the bioreactor volume is at least 900 ml. In one embodiment the bioreactor volume is at least 1000 ml. In one embodiment the bioreactor volume is greater than 1000 ml.
In one embodiment, as the culture volume and/or cell density increases, the rocking rate increases. In one embodiment the rocking rate increases from at least 2 RMP to at least 3 RPM. In one embodiment the rocking rate increases from at least 2 RPM to at least 4 RMP. In one embodiment the rocking rate increases from at least 2 RPM to at least 5 RMP. In one embodiment the rocking rate increases from at least 2 RPM to at least 6 RMP. In one embodiment the rocking rate increases from at least 3 RPM to at least 4 RMP. In one embodiment the rocking rate increases from at least 3 RPM to at least 5 RMP. In one embodiment the rocking rate increases from at least 3 RPM to at least 6 RMP. In one embodiment the rocking rate increases from at least 4 RPM to at least 5 RMP. In one embodiment the rocking rate increases from at least 4 RPM to at least 6 RMP. In one embodiment the rocking rate increases from at least 5 RPM to at least 6 RMP. In one embodiment the rocking rate is at least 2 RPM at a 2° angle. In one embodiment the rocking rate is at least 3 RPM at a 3° angle. In one embodiment the rocking rate is at least 4 RPM at a 4° angle. In one embodiment the rocking rate is at least 5 RPM at a 5° angle. In one embodiment the rocking rate is at least 6 RPM at a 6° angle.
In one embodiment, as the volume of the culture media is incrementally increased to 1000 ml, the rocking rate is incrementally increased to 6 RPM. In one embodiment the volume of the culture media in the bioreactor bag at the start of expansion is about 300 ml at a rocking rate of 2 rpm at a 2° angle maintained
at a perfusion rate of one bioreactor bag volume a day. In one embodiment when the culture reaches a cell density of 4E6 nucleated cells/ml, the volume of the culture media in the bioreactor bag is increased to 600 ml with a perfusion rate of one bioreactor bag volume per day at a rocking rate of 4 rpm at a 4° angle. In a related embodiment when the culture reaches a density of 4E6 nucleated cells/ml, the volume of the culture media in the closed single use bioreactor bag is increased to 1000 ml with perfusion rate of one bioreactor bag volume per day, at a rocking rate of 6 rpm at a 6° angle.
In one embodiment, the culture in the single use bioreactor bag is maintained at 80 - 100% O2.
In one embodiment the cells are expanded for 7 to 14 days. In one embodiment the cells are expanded for 7 to 13 days. In one embodiment the cells are expanded for 7 to 12 days. In one embodiment the cells are expanded for 7 to 11 days. In one embodiment the cells are expanded for 7 to 10 days. In one embodiment the cells are expanded for 7 to 9 days. In one embodiment the cells are expanded for 7 to 8 days. In one embodiment the cells are expanded for 8 to 14 days. In one embodiment the cells are expanded for 8 to 13 days. In one embodiment the cells are expanded for 8 to 12 days. In one embodiment the cells are expanded for 8 to 11 days. In one embodiment the cells are expanded for 8 to 10 days. In one embodiment the cells are expanded for 8 to 9 days. In one embodiment the cells are expanded for 9 to 14 days. In one embodiment the cells are expanded for 9 to 13 days. In one embodiment the cells are expanded for 9 to 12 days. In one embodiment the cells are expanded for 9 to 11 days. In one embodiment the cells are expanded for 9 to 10 days. In one embodiment the cells are expanded for 10 to 14 days. In one embodiment the cells are expanded for 10 to 13 days. In one embodiment the cells are expanded for 10 to
12 days. In one embodiment the cells are expanded for 10 to 11 days. In one embodiment the cells are expanded for 11 to 14 days. In one embodiment the cells are expanded for 11 to 13 days. In one embodiment the cells are expanded for 11 to 12 days. In one embodiment the cells are expanded for 12 to 14 days. In one embodiment the cells are expanded for 12 to 13 days. In one embodiment the cells are expanded for
13 to 14 days. In one embodiment the cells are expanded for 7, 8, 9, 10, 11, 12, 13, 14, or more days. In one embodiment the cells are expanded for at least 7 days. In one embodiment the cells are expanded for at least 8 days. In one embodiment the cells are expanded for at least 9 days. In one embodiment the cells are expanded for at least 10 days. In one embodiment the cells are expanded for at least 11 days. In one embodiment the cells are expanded for at least 12 days. In one embodiment the cells are expanded for at least 13 days. In one embodiment the cells are expanded for at least 14 days.
In one embodiment, the cells are expanded at 34-39°C. In one embodiment, the cells are expanded at 34-35°C. In one embodiment, the cells are expanded at 35-37°C. In one embodiment, the cells are expanded at 35-36°C. In one embodiment, the cells are expanded at 36-37°C. In one embodiment, the cells are expanded at 34°C, 35°C, 36°C, or 37°C. In one embodiment, the cells are expanded at 34°C. In one embodiment, the cells are expanded at 35°C. In one embodiment, the cells are expanded at 36°C. In one embodiment, the cells are expanded at performed at 37°C.
“Engineered T cells” and “genetically engineered T cells”, are used interchangeable and refer to T cells that have been modified by the introduction of extra genetic material, in particular, polynucleotides encoding proteins of interest, such as receptors expressed on a cell surface. Examples of cell surface receptors include chimeric antigen receptors (CAR) and T-cell receptors (TCR). The terms “isolated engineered T cell” and “isolated genetically engineered T cells” specifically refer to T cells that have been modified or manipulated, such as genetic modification, or not normally found in nature. As used herein, T cell or T lymphocyte refers to a type lymphocyte that actively participates in the body’s immune response.
The terms “polynucleotide” and “nucleic acid molecule” are used interchangeably throughout and include both single-stranded and double-stranded nucleic acids and includes genomic DNA, RNA, mRNA, cDNA, or synthetic origin or some combination thereof which is not associated with sequences normally found in nature. The terms “isolated polynucleotide” or “isolated nucleic acid molecule” specifically refer to sequences of synthetic origin or those not normally found in nature. Isolated nucleic acid molecules comprising specified sequences may include, in addition to the specified sequences, coding sequences for up to ten or even up to twenty other proteins or portions thereof or may include operably linked regulatory sequences that control expression of the coding region of the recited nucleic acid sequences, and/or may include vector sequences. The nucleotides comprising the nucleic acid molecules can be ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide. The modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2', 3'- dideoxyribose, and internucleotide linkage modifications such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phoshoraniladate and phosphoroamidate .
The terms “polypeptide” or “protein” are used interchangeably throughout and refer to a molecule comprising two or more amino acid residues joined to each other by peptide bonds. Polypeptides and proteins also include macromolecules having one or more deletions from, insertions to, and/or substitutions of the amino acid residues of the native sequence, that is, a polypeptide or protein produced by a naturally- occurring and non-recombinant cell; or is produced by a genetically -engineered or recombinant cell, and comprise molecules having one or more deletions from, insertions to, and/or substitutions of the amino acid residues of the amino acid sequence of the native protein. Polypeptides and proteins also include amino acid polymers in which one or more amino acids are chemical analogs of a corresponding naturally- occurring amino acid and polymers. Polypeptides and proteins are also inclusive of modifications including, but not limited to, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation. Polypeptides and proteins of interest can be of scientific or commercial interest, including those useful as components of cell therapy therapeutics. Proteins of interest include, among other things, membrane-bound proteins.
The invention provides a method for producing engineered T cells that express a protein of interest. In one embodiment the protein of interest is a cell surface receptor. The cell surface receptor is a genetically engineered receptors such as T cell receptors (TCRs) and chimeric antigen receptors (CARs or CAR-T cells, TRUCKS (chimeric antigen receptors that redirect T cells for universal cytokine-mediated killing), and armored CARs (designed to modulate an immunosuppressive environment)) and as well as other proteins comprising an antigen binding molecule that interacts with that targeted antigen. These engineered receptors are expressed on the surface of the T cell. In one embodiment the cell surface receptor is a T cell receptor or a chimeric antigen receptor.
TCRs are membrane anchored heterodimer protein complexes comprising an a chain and a b chain complexed with the invariant CD3 chain molecules. The variable domain of the TCR a- and b-chains each have three complementarity -determining regions (CDRs) that recognize a peptide derived from the protein presented by /bound within the groove of an MHC/HLA molecule, and a constant domain that engages in disulfide bonding to link the chains together. CD3 and zeta activate the T lymphocyte through signal transduction. The TCR have the potential to recognize antigens presented on the surface of numerous cells, such as cancer cells, inflammatory cells and cells from other sources.
CARs are engineered transmembrane proteins, comprising an extracellular domain, typically comprising an antigen binding protein or domain that binds to an antigen of interest, a hinge region, a transmembrane domain, and an intracellular (cytoplasmic) domain.
The extracellular domain may be derived either from a synthetic or from a natural source, such as the proteins described herein. The extracellular domains often comprise a hinge portion, sometimes referred to as a “spacer” region. Hinges may be derived from the proteins as described herein, particularly the cO- stimulatory proteins described herein, as well as immunoglobulin (Ig) sequences or other suitable molecules to achieve the desired special distance from the target cell.
A transmembrane domain may be fused to the extracellular or intracellular domain of the CAR. The transmembrane domain may be derived either from a synthetic or from a natural source, such as the proteins described herein, particularly the costimulatory proteins described herein.
An intracellular (cytoplasmic) domain may be fused to the transmembrane domain and can provide activation of at least one of the normal effector functions of the immune cell. Effector function includes cytolytic activity or helper activity including the secretion of cytokines. Intracellular domains can be derived from the proteins described herein, particularly from CD3.
CARs can be engineered to bind to an antigen (such as a cell-surface antigen) by incorporating an antigen binding molecule that interacts with that targeted antigen. CARs typically incorporate an antigen binding domain (such as scFv) in tandem with one or more costimulatory (“signaling”) domains and one or more activating domains.
In one embodiment the antigen binding molecule is an antibody fragment thereof, and more preferably one or more single chain antibody fragment (“scFv”). scFvs are preferred for use in CARs because they can be engineered to be expressed as part of a single chain along with the other CAR components. See Krause et al., J. Exp. Med., 188(4): 619-626, 1998; Finney et al., Journal of Immunology, 161: 2791-2797, 1998.
CARs incorporate one or more costimulatory (signaling) domains to increase their potency. See U.S. Patent Nos. 7,741,465, and 6,319,494, as well as Krause et al. and Finney et al. (supra), Song et al., Blood 119:696-706 (2012); Kalos et al., Sci Transl. Med. 3:95 (2011); Porter et al., N. Engl. J. Med. 365:725-33 (2011), and Gross et al., Amur. Rev. Pharmacol. Toxicol. 56:59-83 (2016). Suitable costimulatory domains can be derived from, among other sources, CD28, CD28T, 0X40, 4-1BB/CD137, CD2, CD3 (alpha, beta, delta, epsilon, gamma, zeta), CD4, CD5, CD7, CD8, CD9, CD16, CD22, CD27, CD30, CD 33, CD37, CD40, CD 45, CD64, CD80, CD86, CD134, CD137, CD154, PD-1, ICOS, lymphocyte function-associated antigen- 1 (LFA-1 (CD1 la/CD18), CD 247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class I molecule, TNF, TNFr, integrin, signaling lymphocytic activation molecule, BTLA, Toll ligand receptor, ICAM-1, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD 19, CD4, CD8alpha, CD8beta, IL-2R beta, IL- 2R gamma, IL-7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, IT GAD, CDl-ld, ITGAE, CD 103, ITGAL, CDl-la, LFA-1, ITGAM, CDl-lb, ITGAX, CDl-lc, ITGB1, CD29, ITGB2, CD 18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Lyl08), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD 162), LTBR, LAT, 41-BB, GADS, SLP-76, PAG/Cbp, CD19a, CD83 ligand, or fragments or combinations thereof. The costimulatory domain can comprise one or more extracellular portions, a transmembrane portion, and an intracellular portion.
CARs also include one or more activating domains. CD3 zeta is an element of the T cell receptor on native T cells and has been shown to be an important intracellular activating element in CARs.
Cell surface molecules can be targeted with a traditional CAR. Intracellular molecules can be targeted with TCRs that recognize a peptide derived from the protein presented by or bound within the groove of an MHC/HLA molecule. Such targets include alpha folate receptor, 5T4, AFP, ADAM 17, 17- A, ART-4, anb6 integrin, BAGE. Bcr-abl, BCMA, B7-H3, B7-H6, CAIX, CAMEL, CAP-1, Carbonic anhydrase IX, CASP-8, CDC27m, CD19, CD20, CD22, CD30, CD33, CD44, CD44v6, CD44v7/8, CD70 (CD27L or TNFSF7), CD79a, CD79b, CD123, CD138, CD171, CDK4/m, cadherin 19 (CDH19), Placental-Cadherin (CDH3), CEA, CLL-1, CSPG4, CT, Cyp-B, DAM, DDL3, EBV, EGFR, EGFRvIII, EGP2, EGP40, ELF2M, ErbB2 (HER2), EPCAM, EphA2, EpCAM, ETV6-AML1, FAP, fetal AchR, FLT3, FRa, G250, GAGE, GD2, GD3, 'Glypican-3 (GPC3), GNT-V, GP-100, HAGE, HBV, HCV, HER-
2/neu, HLA-A, HPV, HSP70, HST-2, hTERT, iCE, IgE, IL-llRa, IL-13Ra2, Kappa, KIAA0205, LAGE, Lambda, LDLR/FUT, Lewis-Y, MAGE, MAGE1, MAGEB2, MART - 1 ,/Melan- A, MC1R, MCSP, MUM- 1, MUM-2, MUM-3, mesothelin (MSLN), Mucl, Mucl6, Myosin/m, NA88-A, NCAM, NKG2D Ligands, NY-ESO-1, P15, pl90 minor bcr-abl, PML/RARa, PRAME, PSA, PSCA, PSMA, RAGE, ROR1, RU1, RU2, SAGE, SART, SSX-1, SSX-2, SSX-3, Survivin, TAA, TAG72, TEL/AML1, TEMs, TPI, TRP-1, TRP-2, TRP-2/INT2, VEGFR2 and WT1. See also, Loffler etal., Blood 85(6): 2098-2103, 15 March 2000; Wolf et al., Drug Discovery Today 10(8): 1237-1244, September 2005; Baeuerle & Reinhardt, Cancer Res 69(12): 4941-4944, June 15, 2009; Baeuerle et al., Curr. Opin, Mol. Ther. 11: 22-30, 2009; Nagorsen & Baeuele, Exp Cell Res 317:1255-1260, 2011; Nagorsen etal., Pharmacology & Therapeutics 136: 334-342, 2012; Huehls et al., Immunology and Cell Biology 93:290-296, 2015; and Stieglmaier et al., Expert Opin Biol Ther 15(8): 1093-1099, 2015.
The process could be used for producing T cells expressing the CD 19 CARs, such as Tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Y escarta®).
In one embodiment the cell surface receptor recognizes an antigenic target associated with a target cell such as a cell surface molecule or an intermolecular molecule. The target cell is any cell that presents an antigen that is recognized by the gene of interest. In one embodiment the target cell is a cancer cell. A cancer cell is a cell associated with a cancer, including cells associated with metastatic tumors, solid tumors, blood cancers, brain cancers, breast cancers, colon cancers, kidney cancers, lung cancers, liver cancers, ovarian cancers, pancreatic cancers, prostate cancers, skin cancers, spleen cancers, stomach cancers, thyroid cancers.
Greater transduction efficiency allows for delivering a smaller, more effective dose to the patient. When fewer T cells transduced with the gene of interest are produced there are fewer genetically engineered T cells available for administration to the patient resulting in a less effective dose. The method described herein achieves a high transduction rate (high transgene expression greater than 40% on CD8 T cells) at a lower lentiviral vector MOI. Less lentiviral vector is required to make more engineered T cells expressing the protein of interest, the method is more efficient and cost effective. The invention provides a method for increasing the transgene expression in genetically engineered autologous T cells expressing a protein of interest, the method comprising inoculating a closed single use bioreactor bag containing culture media with apheresed donor cells and one or more soluble T cell activators, wherein at least one soluble T-cell activator is bound to at least one donor cell at the time of inoculation and the bioreactor bag is part of a rocking bioreactor platform, culturing the cells in the closed single use bioreactor bag continuously rocking at a rate of about 2 RPM, transducing the cells in the closed single use bioreactor bag with at least one soluble viral vector comprising a polynucleotide which encodes the protein of interest continuously rocking at a rate of about 2 RPM, and expanding the cells in the closed single use bioreactor bag at a rocking rate of about 2 RPM and increasing the culture volume and rocking the rate as needed to maintain the culture until harvest, wherein the transgene expression is greater than the transgene expression of genetically
engineered autologous T cells derived from an enriched population of T cells from the same apheresed donor cells and expressing the same protein of interest.
Genetically engineered T cells are recovered by harvesting when the cell density has reached a desired or predetermined state or at a predetermined or desired time point. The genetically engineered T cells may be recovered from the bioreactor using methods known in the art, such as separation using gravity or centrifugation. The cells may also be recovered using semiautomated and fully automated cell separation systems, including blood separation systems. Such systems are commercially available and include Sepax® 2 and Sefia™ S-2000 Cell Processing Systems (GE Healthcare), Cobe 2991 cell processor (Terumo BCT, Lakewood, CO, CellSaver 5 (Haemonetics, (Boston, MA), and the like. The recovered cells are typically washed and concentrated into a suitable formulation for administration to the patient and for cryopreservation.
With the method described herein, yields of greater than 10 billion with a viability of greater than 90% are seen in a 10 day process. Yields greater than 20 billion were seen after when cell expansion was extended for several more days.
Samples may be taken during expansion and/or at harvest for quality control testing. Such QC tests may include those that quantify the transduction efficiency of the genetically engineered T cells such as determining % TCR on cell surface using flow cytometry and determining vector copy number using qPCR to measure integration. Viability can also be tested before releasing the product to be delivered to the patient.
Standard procedures known in the art may be used for cryopreservation of recovered genetically engineered T cells for storage and/or preparation for use in a human subject. In one embodiment the recovered cells are eluted at 2E8 cells/ml in saline supplemented with 1% HSA and were further formulated at a 1:1 ratio with Hy clone cryopreservation media (GE Healthcare) supplemented with 5% human serum albumin.
A fraction of the formulated engineered T cells, as well as any apheresed cells not used in the method, can be cryopreserved by methods known in the art to provide a permanent source of such cells for the future treatment of the patient.
When needed for treatment, the cryopreserved genetically engineered T cells are thawed and diluted into a saline buffer or other suitable media for administration to the donor by infusion in a treatment- effective amount. Suitable infusion media can be any isotonic medium formulation, typically normal saline, Normosol™ R (Abbott) or Plasma-Lyte™ A (Baxter), but also 5% dextrose in water or Ringer's lactate can be utilized. The infusion medium can be supplemented with human serum albumin. The volume is typically kept minimal as possible, a pharmaceutically acceptable dose is based on the number and viability of the cells, the indication to be treated and the patient. Therapeutic doses are typically between a few
million and a few billion cells, depending on the patient’s condition and need, among other factors. An exemplary dose may be <100 ml at about 100E6 cells/ml.
The invention provides a method of treating a patient with genetically engineered autologous T cells expressing a protein of interest comprising, incubating apheresed cells from the patient with one or more T cell activators selected from the group consisting of an anti CD3 antibody, an anti CD2 antibody, and an anti CD28 antibody or binding fragments thereof, to allow for saturation of antibody binding, inoculating a closed single use bioreactor bag containing culture media with the apheresed cells, wherein the bioreactor bag is part of a rocking bioreactor platform, culturing the cells in the closed single use bioreactor bag continuously rocking at a rate of about 2 RPM, transducing the cells in the closed single use bioreactor bag with at least one soluble viral vector comprising a polynucleotide which encodes the protein of interest continuously rocking at a rate of about 2 RPM, and expanding the cells in the closed single use bioreactor bag at a rocking rate of about 2 RPM, increasing the culture volume and rocking the rate as needed to maintain the culture at a desired cell density until harvest, harvesting and formulating the cells for cryopreservation, freezing the cells and storing until needed for administering to the patient, thawing and resuspending the cells in a suitable media for infusion, and reintroducing a pharmaceutically effective amount of the genetically engineered autologous T cells expressing the protein of interest into the patient.
The formulated engineered T cells may be administered either alone, or as a pharmaceutical composition in combination with diluents and/or with other components such as IL-2 or other cytokines or cell populations.
Methods are provided for using the engineered T cells for treating conditions, indications, diseases, disorders and the like. The T cell expresses a gene of interest, such as a cell surface receptor, recognizes an antigenic target associated with a target cell that is associated with the condition, indication, disease, disorder or the like. Such conditions, diseases or disorders including cancers, tumors, solid tumors, hematologic disorders, leukemia, lymphomas, viral infections, inflammatory disease or disorders, and/or autoimmune disease or disorders. In one embodiment of the invention, the genetically engineered T cells are used to treat an indication in a subject. In one embodiment of the invention, genetically engineered T cells are used to treat a cancer patient. In some embodiments, the invention provides creating a T cell- mediated immune response in a donor, comprising administering to the donor an effective amount of an engineered autologous T cell that expresses a protein of interest. In some embodiments, the T cell-mediated immune response is directed against a target cell or cells. In some embodiments, the engineered autologous T cell comprises a genetic construct expressing one or more chimeric antigen receptors, T cell receptors and/or other proteins of interest. In some embodiments, the target cell is a tumor cell. In some embodiments, the invention comprises a method for treating or preventing an indication, said method comprising administering to a subject in need thereof an effective amount of a genetically engineered autologous T cell made by the method described herein. In some aspects, the invention comprises a method for treating or preventing inflammatory and/or autoimmune disorders.
While the terminology used in this application is standard within the art, definitions of certain terms are provided herein to assure clarity and definiteness to the meaning of the claims. Units, prefixes, and symbols may be denoted in their SI accepted form. Numeric ranges recited herein are inclusive of the numbers defining the range and include and are supportive of each integer within the defined range. The methods and techniques described herein are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. All documents, or portions of documents, cited in this application, including but not limited to patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference. The present invention is not to be limited in scope by the specific embodiments described herein that are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims. What is described in an aspect or embodiment of the invention can be combined with other aspects and/or embodiments of the invention.
EXAMPLES
Example 1 Comparison study of three processes
1 : Autologous T cells generated with the closed continuous autologous T cell bioprocessing method where activation to expansion is conducted in a Xuri W25 Cell Expansion System. “Xuri W25 bioreactor”.
2: A bioprocessing system where activation to expansion is conducted in G-Rex® 6 and 24 well plates. “G-Rex”.
3: Hybrid bioprocessing system where activation and transduction are conducted in a gas permeable bag followed by T cell expansion in a Xuri W25 Cell Expansion System. “Permeable bag”.
In addition, two different culture media supplemented with IL2 (Media 1) or TWS119 + IL7 + IL21 (Media 2), were also compared using the closed continuous autologous T cell bioprocessing system and the G-Rex® plates.
T cell production was evaluated for its purity, phenotype, and in vitro properties.
On day 0, a fresh Leukopack® (Hemacare, Northridge, CA), containing 300 ml fresh leukapheresis product collected from normal peripheral blood was sterile welded to a CD-600.1 Sepax Cell Separation Kit (GE) and processed under the Culture Wash-Pro program. The Leukopack® contained leukocytes, erythrocytes, and platelets. The cells were washed in 1L ClinMACS PBS/EDTA, 5ml human serum albumin (Miltenyi Biotec, San Diego, CA) to remove plasma and any apheresis buffers using a Sempax CPro Cell Separation System equipped with a CS-600.1 Kit (GE Healthcare), according to manufacturer’s instructions. Based on the initial white blood cell (WBC) count indicated on the donor information sheet accompanying the Leukopack®, the cells were eluted at a cell density of 150E6 WBC/ml with ~50 ml OpTimizer complete media.
The nucleated cells in the washed leukapheresed harvest sample were counted using NC-200™ Automated Cell Counter ChemMetec, Denmark) and followed by determining total viable cell count, viability, and immunophenotyping of the washed cells.
1) Closed continuous autologous T cell bioprocess using the a Xuri W25 Cell Expansion System. “Xuri W25 bioreactor”
A portion of the washed apheresed donor cells comprising 1.2E9 nucleated cells was then transferred into two transfer bags (Charter Medicine, Winston-Salem, NC) under the Dilute program using the Sepax C-Pro processing system with the same CD-600.1 Kit. In to one bag was added about 8 ml of Media 1 : (OpTmizer complete media containing 300 IU/mL rhIL2 (ThermoFisher)). In to the second bag was added about 8 ml of Media 2: (OpTmizer complete media containing 5uM TWS119 (Cayman Chemical, Ann Arbor, MI), 20ng/ml IL7 (Stemcell Technologies, Cambridge, MA) and 20ng/ml IL-21 (Stemcell Technologies)). Each bag was incubated with 7.5 ml ImmunoCult™ Human CD3/CD28/CD2
(25 mΐ/ml of cells, Stemcell Technologies) at room temperature for 1 hour to allow saturation of antibody binding. The concentration of the Immunocult added was determined on a final activation culture volume of 300 ml as described in the step below. OpTmizer complete media: OpTimizer T cell expansion medium (ThermoFisher, Waltham, MA), 2.5% Immune Cell SR supplement (ThermoFisher), 2.6% CTS T cell supplement (ThermoFisher), 1% GlutaMax (ThermoFisher), 0.1% Pluronic F68 and 300IU/ml IL2.
A 2L Xuri SP Perf Cellbag bioreactor (GE Healthcare) was connected to a Xuri Cell Expansion System W25 and 300 ml Media 1 was added and allowed to equilibrate at 37°C, 5% C02, gas flow rate of 0.1 L/min, and a rocking rate of 6 rpm at a 6° angle. A second 2L Xuri SP Perf Cellbag bioreactor was also connected to a Xuri Cell Expansion System W25 and 300 ml Media 2 was similarly equilibrated.
The transfer bags containing the cells in Media 1 and Media 2 were sterile welded to the Xuri Cellbag feed-lines and the contents transferred into the bags by gravity. The cells were then cultured overnight at 37°C, 5% C02, gas flow rate O.lL/min at a rocking rate of 2 rpm at a 2° angle to allow for the activation of T cells.
On Day 1, the nucleated cells in each bag were counted. An amount of a lentiviral vector (comprising a polynucleotide encoding a TCR) that corresponded to a MOI of 1 functional titer was diluted in 10ml of Media 1 or Media 2 and placed in transfer bags. The transfer bags were sterile welded on to the Xuri Cellbag feed-lines and lentivirus was transferred into each of the bioreactors via gravity flow. The cells were incubated at 37°C, 5% C02, gas flow rate of 0.1 L/min, and a rocking rate of 2 rpm at a 2° angle, for 20 - 24 hours.
On Day 2, about half the volume of the culture media in each bioreactor bag was exchanged using three 50ml bag washouts through feed-line and waste-line. Cell counts were taken daily and viable cell density (VCD) and viability were determined using NC200™ Automated Cell Counter (ChemMetec), dissolved oxygen and metabolites were also measured. Cell phenotypes were determined for all samples tested. The bags were maintained on the rocking bioreactors at 2 rpm at a 2° angle, 37°C, 5% C02, gas flow rate of 0.1 L/min, for 24 hours.
On Days 3-7, additional OpTimizer complete media containing either the IL-2 (Media 1) or TWS119/IL17/IL21 (Media 2), was added by fed batch/perfusion feeds to a final volume of 1L to both cultures, to maintain the cell density above 2E6 cells/ml. As volume increased, the rocking speed and angle was increase to 4RPM at a 4° angle, to maintain a cell density at the desired level.
Total viable cell density, viability, glucose and lactate measurements were taken each day. Phenotyping was determined on days 3, 5 and 7.
On Days 7-10, both cultures were switched to perfusion feeding at a rate of one bag volume/day. Both bioreactor bags were now fed with Media 1. As cell density increased, dissolved 02 levels were maintained at 80% by feedback control.
Total viable cell density, viability, glucose, and lactate measurements were made each day. Phenotyping was done on day 10.
The cells were harvested on Day 10. The Xuri SP Per bioreactor bags were sterile welded to a Selfia 5200 Cell Processing System using the FlexCell program and CT-800.1 Cell Processing kit (GE Healthcare. The T cells were concentrated to ~20ml at a 75ml/min flow rate. One wash cycle was performed using 0.9% saline (Baxter, Deerfield, Ill) supplemented with 1% vol human serum albumin (HSA). The wash was performed at 380 X g for 5 min.
Cells were reconstituted in equal volume saline plus 1% HSA plus Hy Clone™ Cryopreservation Media (GE Healthcare) supplemented with 5% HSA and cryopreserved by freezing to -80°C using the control rate freezer Via Freeze (GE Healthcare) and storing in liquid nitrogen.
2. G-rex Plates “G-Rex”.
The cells were cultured in 24-well or 6-well G-Rex® (WilsonWolf, New Brighton, MN) plates following manufacturer’s protocols, using Media 1 and Media 2. 1E6 cells/well were seeded in the G-Rex® plates and activated with ImmunoCult™ Human CD3/CD28/CD2 (25ug/ml media with cells) on day 0. Approximately 24 hours after activation, cells were seeded at 1E6 cells/well (concentration 2E6 cells/mL) and an amount of the same lentiviral vector (comprising a polynucleotide encoding a TCR), corresponding to a MOI of 1 functional titer was added to each well. On day 2, Media 1 and Media 2 was added to the full capacity of the wells (total 6 mL) to dilute the virus. The media was changed, and the cells were fed every 2-3 days.
Cell counts were taken daily and viable cell density (VCD) and viability were determined using a NC-200™ Automated Cell Counter (ChemoMetec), dissolved oxygen and metabolites were also measured. Cell phenotypes were determined for all samples tested.
3. Hybrid bioprocessing system, activation and transduction conducted in a gas permeable bag followed by T cell expansion in a Xuri W25 Cell Expansion System. “Perfusion bag”.
Washed apheresed donor cells comprising 500E6 nucleated cells was transferred into a gas permeable bag (OriGen, Austin, TX) with 6 ml ImmunoCult™ Human CD3/CD28/CD2 and incubated at 37°C, 5% C02 for 24 hours.
The nucleated cells were counted. An amount of the same lentiviral vector (comprising a polynucleotide encoding aTCR), corresponding to a MOI of 1 functional titer was added directly to the bag using a syringe and incubated overnight at 37°C, 5% C02.
The cells were then split into two gas permeable bags the following day and were incubated in the bags at 37°C, 5% CO2, until a total of 1 billion nucleated cells.
The cells were then inoculated into 2L Xuri SP Perf Cellbag bioreactor bags on a Xuri W25 Cell Expansion System (GE Healthcare) containing 300 ml OpTimizer complete media containing 300 IU/ml IL2, and rocked at a rate of 6 rpm at a 6° angle. The bioreactor was scaled up to a 1L volume 24 hours following inoculation. Fresh media was perfused at 500ml/day for 1 day, followed by lL/day until harvest.
Cell counts were taken daily and viable cell density (VCD) and viability were determined using a NC-200™ Automated Cell Counter (ChemoMetec), dissolved oxygen and metabolites were also measured. Cell phenotypes were determined for all samples tested.
The cells were harvested, concentrated and further formulated at a 1:1 ratio with HyClone™ Cryopreservation Media (GE Healthcare) supplemented with 5% HSA and cryopreserved by freezing to 100°C using a Via Freeze (GE Healthcare) and storing in liquid nitrogen. Viability and recovery at harvest were measured.
Results
Figure 1 Shows the growth curve and TCR expression at harvest for the T cells produced under Condition 1, the closed continuous autologous T cell bioprocess using the Xuri W25 bioreactor. Figure 1 A shows the growth curve of cell expansion in the Xuri W25 bioreactor with media supplemented with IL2 only or the cocktail of IL7, IL21, and TWS119. Media with IL2 yielded 16 billion T cells in 10 days while media with IL7, IL21, and TWS119 yielded 12 billion T cells in 10 days. Figure IB shows the viability of cell expanded in the Xuri W25 bioreactor with media supplemented with IL2 only or the IL7, IL21, and TWS119 cocktail. Cell viability was above 90% throughout expansion and no difference in cell viability was observed between the different media conditions.
Figure 2 shows T cell transgene expression under different conditions. All cells were transduced with the same lentiviral vector at a MOI=l one day after activation. The transgene was more highly expressed in the cells transduced in the Xuri W25 bioreactor compared with cells transduced in the Permeable bag (Hybrid condition 3) or in the G-Rex system (condition 2).
Figure 3 shows the leukocyte subsets in harvested T cells from the different test conditions. Analysis of human B cells (CD19), monocytes (CD14), NK cells (CD56/16), NKT cells (CD3+ CD56+), and T cells (CD3+ Cd56-) were performed by immunophenotyping. T cell purity in all conditions were above 98% and no significant difference in the percentage of non-T cells subsets was seen among the different conditions.
Figure 4 shows the percentage of T cells subsets on Day 5 (A) and Day 10 (B) under different conditions. Tscm, Tcm, Tem, and Tte subsets were analyzed by immunophenotyping based on their expression of CD45RA, CD45RO, CD95, and CCR7. T cells produced in the Xuri W25 bioreactor had a higher percentage of Tscm and Tcm than T cells produced in the G-Rex system or Permeable bag on Day5 and a higher percentage of Tcm on Day 10 than T cells that was produced in the G-Rex system, indicating a less differentiated phenotype.
Figure 5 shows the cytotoxic function of engineered T cells characterized by their ability in target cell lysis (A), IFN-gamma release in response to target cells (B), and TNF-alpha release in response to target cells (C). Briefly, harvested T cells and peptide -pulsed T2 cells were co-cultured together at a ratio of 1:1. The T2 cells were Luiferase engineered, and luminescence was determined using a Steady-Glo® Luciferase Assay System (Promega, Madison, WI). The decrease of luminescence was used to quantify the cell death of T2 cells as an indicator of the cytotoxicity of engineered T cells. As shown in the figures, engineered T cells generated in the Xuri W25 bioreactor under the two media conditions (IL2 or IL7, IL21, TWS119) were both more potent in killing target cells (A), possibly due to their stronger release of IFN- gamma (B) and TNF-alpha (C), than engineered T cell generated in the static Permeable bag and the static G-Rex system.
Figure 6 shows resistance to target cell challenge of engineered T cells, characterized by their level of annexin (A) and expression of exhaustion marker Tim3 (B) after co-culturing with target cells in vitro at effector to target (E:T) ratio at 1:1. Extemalization of phosphatidylserine in apoptotic cells was detected using recombinant annexin V conjugated to violet-fluorescent Pacific Blue™ dye. T cells with effector phenotype are susceptible to activation with target cell challenge and will become apoptotic after activation, thus a lower level of annexin should indicate T cells with more memory subsets. As shown in the figures, engineered T cells generated from the Xuri W25 bioreactor had lower level of annexin than cells from G- Rex system or Permeable bag in response to target cell challenge, thus are more memory phenotype-like. (A). In addition, engineered T cells generated in the Xuri W25 bioreactor and Permeable bag had lower expression of exhaustion marker Tim3 compared with cells from G-Rex system (B).
The closed continuous autologous T cell bioprocessing method was compared with the static G- Rex and hybrid gas permeable bag/Xuri system in their ability to generate autologous lentiviral engineered T cells. The closed continuous method produced T cells with higher transgene expression, higher level of cytokine secretion, and more memory -like phenotype when compared with T cells transduced in the static G-Rex system or the static gas permeable bag.
Example 2 Addition of a glycolysis inhibitor to the culture media
On day 0, a fresh Leukopack® (Hemacare, Northridge, CA), containing 300 ml fresh leukapheresis product collected from normal peripheral blood was sterile welded to a CD-600.1 Sepax Cell Separation Kit (GE Healthcare) and processed under Culture Wash-Pro program. The Leukopack® comprised
leukocytes, erythrocytes, and platelets. The cells were washed in 1L ClinMACS PBS/EDTA, 5ml human serum albumin (Miltenyi Biotec) to remove plasma and apheresis buffers using a Sempax CPro Cell Separation System equipped with a CS-600.1 Kit (GE Healthcare), according to manufacturer’s instructions. The cells were washed and counted as described above in Example 1.
A portion of the washed apheresed donor cells comprising 1.2E9 nucleated cells were transferred into two transfer bags under the Dilute program using Sepax C-Pro processing system with the same CS- 600.1 Kit (a new kit was not used). Into one bag was added about 8 ml of Media 1 (OpTmizer complete media containing 300 IU/mL rhIL2 (ThermoFisher) and 2mM 2-Deoxy-D-glucose (2-DG) (Millipore Sigma, Burlington, MA)). Into the second bag was added about 8 ml of Media 2 (OpTmizer complete media containing 300 IU/mL rhIL2 (ThermoFisher)). To each was added 7.5 ml Immunocult anti-CD3/CD28/CD12 (25pl/ml media with cells, Stemcell Technologies). The amount of activator was determined based on the culture volume of 300 ml that was used in the culture/activation step below. The bags were incubated for 1 hour at room temperature to allow for saturation of antibody binding.
A 2L Xuri SP Perf Cellbag bioreactor (GE Healthcare) was connected to a Xuri Cell Expansion System W25 and 300 ml Media 1 was added and allowed to equilibrate at 37°C, 5% CO2, gas flow rate of 0.1 L/min, and a rocking rate of 6 rpm at a 6° angle. A second 2L Xuri SP Perf Cellbag bioreactor was also connected to a Xuri Cell Expansion System W25 and 300 ml Media 2 was similarly equilibrated.
The transfer bags containing the cells in Media 1 and Media 2 were sterile welded to the Xuri Cellbag feed-lines and the contents transferred into the bags by gravity. The cells were then incubated overnight at 37°C, 5% CO2, gas flow rate 0. lL/min at a rocking rate of 2 rpm at a 2° angle.
On Day 1, the nucleated cells in each bag were counted and the amount of a lentiviral vector (comprising a polynucleotide encoding a TCR) corresponding to a MOI of 1 functional titer was diluted in 10 ml of Media 1 or Media 2 and placed in transfer bags. The transfer bags were sterile welded on Xuri Cellbag feed-lines and the lentivirus was then transferred into each of the bioreactors via gravity flow. The cells were incubated at 37°C, 5% CO2, gas flow rate of 0.1 L/min, and a rocking rate of 2 rpm at a 2° angle, for 20 - 24 hours.
On Day 2, about half the volume of the culture media in each bioreactor bag was exchanged using three 50 ml bag washouts through feed-line and waste-line. Cell counts were taken daily and viable cell density (VCD), viability, dissolved oxygen, metabolites were determined as described above. Cell phenotypes were determined for all samples tested. The bags were maintained on the rocking bioreactors at 2 rpm at a 2° angle, 37°C, 5% CO2, gas flow rate of 0. f L/min, for 24 hours.
On Days 3-9, additional OpTimizer complete media containing either IL-2/2-DG (Media 1) and IL2 (Media 2), were added by fed batch/perfusion feeds to 1L, to maintain the cell density above 2E6 cells/ml. As the culture volume increased, the rocking speed and angle were increase to 4 RPM at a 4°
angle, to maintain a sufficient mass transfer in bioreactors. Media 1 containing 2-DG was perfused out with OpTimizer complete media containing only IL2 (Media 2) when culture volume reached 1L. In a separate experiment, OpTimizer complete media containing 2-DG was maintained until harvest.
Total viable cell density, viability, glucose and lactate measurements were taken each day. Phenotyping was determined on Days 3, 5 and 7.
On Days 9-14, both cultures were switched to lL/day perfusion feeding, and rocking was set at 6 RPM at a 6° angle. Total viable cell density, viability, glucose, lactate measurements were made each day. Phenotyping was done on Day 14.
Total viable cell density, viability, glucose and lactate measurements were taken each day. Phenotyping was determined on Days 9 and 14.
The cells were harvested on Day 14. The Xuri SP Per bioreactor bags were sterile welded to a Selfia 5200 Cell Processing System using the FlexCell program and CT-800.1 Cell Processing kit (GE Healthcare). T cells were concentrated to ~20ml at a 75mFmin flow rate. One wash cycle was performed using 0.9% saline (Baxter, Deerfield, Ill) supplemented with 1% vol human serum albumin (HSA). The wash was performed at 380 X g for 5 min.
Viability and harvest recovery were measured. The cells were concentrated and further formulated at a 1: 1 ratio with Hy clone supplemented with 5% human serum albumin and cryopreserved by freezing to -80°C using a Via Freeze (GE Healthcare) and storing in liquid nitrogen
Results
During antigen stimulation, T cells shift to a glycolytic metabolism to sustain effector function. However, the role of glucose metabolism in T cell differentiation during in vitro expansion is unclear. It was hypothesized in this study that glucose metabolism, in particular glycolysis, supported T cell differentiation into effector phenotype during expansion and pharmacological inhibition of glycolysis via 2-DG could attenuate CD3/CD28/CD2 antigen-mediated differentiation and promote a memory phenotype. In this experiment, 2-DG was added to cells with the activators to inhibit glycolysis following T cell activation. 2-DG was then either removed later in the expansion phase to allow restoration of glycolysis to support cell expansion or kept in through the entire process until harvest. The engineered T cells derived from 2-DG-inhibited T cells differentiation produced more Tscm and Tcm compared with the T cells derived from the media without 2-DG. This resulted in a greater T cell yield, greater transgene expression, and a more memory -like phenotype of the T cells.
Figure 7 shows the growth curve (A) and viability (B) cells expanded in media supplemented with (Media 1) 2-DG and without 2-DG (Media 2). Media containing 2-DGyielded 35 billion T cells in 14 days while medium condition without 2-DGyielded 25 billion T cells in 14 days. Overall viability was above
70% with the cells from the 2-DG media having a slightly higher viability than those from non-2-DG media from Day 4 to Day 10. This drop of viability during Days 4-10 was possibly due to cell death of non-T cell leucocytes. Viability returned to higher than 90% until harvest after the T cell population was enriched to greater than 90% in the cultures. With 2-DG checking the brake onT cells differentiating into Tem, less cytotoxic cytokine release associated with decreased Tem population may also have contributed to higher viability in the samples containing the 2-DG media.
Figure 8 shows transgene expression of cells expanded in the media supplemented with 2-DG (Media 1) and without 2-DG (Media 2). Transgene expression by T cells in 2-DG media was slightly higher than that of T cells in non-2-DG media (56% vs 54%) and was able to maintain at a high level (50.4%) when cell density was as high as 35 billion cells/ml. In contrast, transgene expression of T cell in non-2- DG media decreased to 44.4% at high cell density (25 billion cells/ml).
Figure 9 shows CD25 expression by cells expanded in the media supplemented with 2-DG (Media 1) and without 2-DG (Media 2). CD25 expression by T cells in non-2-DG media showed a stronger response to activation that it expressed at a higher level than that of T cell in 2-DG media (46% vs 32%). Even through CD25 expression by T cells in both conditions saturated at ±80%. T cells in 2-DG media retained CD25 better at Days7 and 9 than the cells in the non-2-DG media. This may be due to the higher transgene expression and T cell yield for T cells generated in the 2-DG media.
Figure 10 shows glucose (A) and lactate (B) concentrations under the different media conditions. Glucose and lactate were measured using Cedex Bio Analyzer (Roche, Indianapolis, IN). Inhibition of glycolysis under the 2-DG media condition (Media 1) was evidenced by higher glucose concentration (lower glucose consumption) (A) and higher lactate concentration (B) in spent media compared to that from the non-2-DG condition (Media 2). In addition, the effect of 2-DG was reversible as restoration of glucose (A) and lactate (B) levels was found after removal of 2-DG from the media from Day 7 to 14.
Figure 11 shows T cell differentiation phenotyping of cells expanded media supplemented with (Media 1) and without 2-DG (Media 2). 2-DG was added to culture medium between Days 0 and 7 and the feed medi was replaced with non-2-DG media (Media 1) from Days 7-14. The T cells in the 2-DG media were less differentiated, suggested by higher Tscm subset (26% vs 14%) at Day 5 and higher combined Tem and Tscm (86% vs 56%) at Day 7. The T cells continued differentiation after 2-DG was perfused out from culture media and ended at a similar level of differentiation as T cells in non-2-DG media (Media 1).
Figure 12 shows leukocyte subsets in harvested T cells under the different media conditions. Analysis of human B cells (CD19), monocytes (CD14), NK cells (CD56/16), NKT cells (CD3± CD56±), and T cells (CD3± Cd56-) were performed by immunophenotyping. Although NKT cells expanded from 5% to ±10%, CD3± cell purity in both conditions was above 98% and no significant difference in the percentage of non-T cells subsets were found between 2-DG and non-2-DG media conditions.
Figure 13 shows the results from potency assays of engineered TCR T cells. T2 cells expressing Luciferase were pulsed with the peptide recognized by the engineered TCR or with DMSO for 4 hours and
the cells were washed before setting up a co-culture assay with 20,000 total T cells at a 1 : 1 (E:T) ratio. (A) 48 hours later, the luciferase signal was measured using the Steady Glo® Luciferase Assay System (Promega). Specific cytotoxicity was measured relative to the no peptide T2 cells cultured with the TCR T cells. (B) IFN-g expression was measured using the AlphaLISA detection kit (Perkin Elmer Waltham, MA) after 24 hours of co-culture. No significant difference in T2 cell lysis was found between T cells in either 2-DG media or non-2-DG media at high peptide concentration (ImM) and slightly higher T2 cell lysis was found for T cells at non-2-DG media than at lower peptide concentration (lOnM). In addition, 24 hour accumulated release of IFN-g was higher for T cells in non-2-DG media cross all concentration of peptide tested. The lower level of IFN-g for T cells in 2-DG media at early timepoint (24 hours) might be due to lag. Further data (not shown here) suggested that activation in T cells from 2-DG media had a more prolonged activation than in T cells from non-2-DG media, which could not be captured in a short-term IFN-g assay. (C) shows differentiation of T cells under different media conditions. Culture media containing 2-DG was used throughout the entire process (10 days). T cells from the 2-DG media were less differentiated as suggested by the higher percentage of collected Tscm and Tcm subsets compared to the T cells from the non-2-DG media (59% vs 43%). This data suggests supplementing 2-DG in culture media for the entire process until harvest.
Example 3
This experiment compared CAR and TCR transduction of cells from an apheresed cell sample from a donor (Unenriched) with cells from the same apheresed cell sample that was further enriched for T cells (Enriched).
On day 0, a fresh Leukopack® (Hemacare, Northridge, CA), containing 300 ml fresh enriched leukapheresis product collected from normal peripheral blood was sterile welded to a CD-600.1 Sepax Cell Separation Kit (GE) and processed under the Culture Wash-Pro program. The Leukopack® contained leukocytes, erythrocytes, and platelets. The cells were washed to remove plasma and apheresis buffers as described above in Example 1 and the nucleated cells were counted using NC-200™ Automated Cell Counter and split equally into two transfer bags (Sample 1, Enriched T cells) and (Sample 2, Unenriched apheresed donor cells) using the Sepax C-Pro cell processing system Dilute program.
For Sample 1, “Enriched T cells”, the T cells were isolated from the washed apheresed cells using an Easy Sep™ Human pan T negative selection kit (Stemcell Technologies) according to the manufacturer’s instructions. The enriched T cells were added to a gas permeable bag at cell density 4E6 nucleated cells/ml in 120ml Optimizer complete media containing 300IU IL2. The gas permeable bag was previously coated with 1.23g/ml anti-CD3 antibody (Miltenyi Biotec) in PBS. Soluble anti-CD28 antibody (Miltenyi Biotec) was added to the permeable bag at 1:100 (Im/ml) dilution afterward for activation.
For Sample 2, “Unenriched apheresed donor cells”, same cell density (4E6 nucleated cells/ml) was added into 120ml Optimizer complete media (containing 300IU/ml IL-2) into a gas permeable bag that was
previously coated with anti-CD3 antibody as for Sample 1. Soluble anti-CD28 antibody (Miltenyi Biotec) was added to the permeable bag at 1:100 (Im/ml) dilution afterward for activation.
Day 1 The nucleated cells in each gas permeable bag were counted and the amount of lentiviral vector comprising a polynucleotide encoding a TCR corresponding to a MOI of 1 (TCR) functional titer was added to one bag, a lentiviral vector comprising a polynucleotide encoding a CAR corresponding to a MOI of 40 (CAR) functional titer was added directly to a second bag, and a lentiviral vector comprising a polynucleotide encoding green fluorescent protein (GFP) was added to the third gas permeable bag. The bags were incubated at 37°C, 5% CO2, overnight.
Days 2-6: On Day2, an additional 120ml OpTmizer complete medium containing 300 IU/ml IL-2 was added into each gas permeable bag to dilute the lentivirus.
Cells from each gas permeable were split into two bags on day 4, and on Day 6 were the bags were inoculated into equilibrated Xuri SP Perf bioreactor bags on Xuri W25 bioreactors (as described in Example 1), reaching a total volume of 800 ml culture media. The bioreactors were rocked at a rate of 6 rpm and at a 6° angle, at 37°C, 5% C02, gas flow rate of 0.1 L/min the entire time of expansion.
Days 7-13 or 14: On Day 7, the volume of culture media in the bioreactors was scaled up to 1L. The cells were kept in bioreactor until Day 13 or 14, when they were harvested. During expansion, OpTimizer Complete media containing 300 IU/ml IL-2 was perfused at a rate of 500 ml/day on Day 8, at a rate of 800 ml/day on Day 9, and at a rate of lL/day from Day 10 until the time of harvest. Cell counts, viable cell density, cell viability, and metabolites were measured each day.
The cells were harvested on Day 13 or 14. The bioreactor bags were sterile welded to a Sepax Pro using Culture Wash program and CT-600 Cell Processing kit (GE Healthcare). One wash cycle was performed using saline (Baxter) supplemented with 1% vol human serum albumin (HSA). The wash was performed at 380 X g for 5 min.
Viability and harvest recovery were measured. The cells were concentrated and further formulated at a 1:1 ratio with HyClone™ Cryopreservation Media (GE Healthcare) supplemented with 5% human serum albumin and cryopreserved by freezing to 100°C using a Via Freeze (GE Healthcare) and storing in liquid nitrogen.
Results
Using unenriched apheresed donor cells as starting material improved transduction efficiency as seen in the level of surface expression and genome integration compared with using enriched-T cells as starting material. In addition, unenriched-cells from apheresis promoted a less-differentiated T cell phenotype. Two out of the three donors tested showed a higher percentage of Tscm and Tcm upon harvest in both CD4+ and CD8+ T cell subsets. T cell purity was comparable between using enriched- vs unenriched- T cells as starting material.
Figure 14 shows transgene expression of T cells at harvest from enriched- and unenriched-cells. Three different lentiviral vectors delivering a CAR, a TCR, or a GFP were transduced into the enriched- and unenriched-donor cells. Transgene expression was detected via antibody staining for the CAR, dextramer staining for the TCR, and fluorescent signal for GFP, using flow cytometry. CAR, TCR, and GFP were higher in CD8 T cells from unenriched cells than from CD8+ T cells from enriched process (A). Dextramer staining was CD8 receptor dependent, thus CD4 T cells did not show expression of TCR (B). However, CAR and GFP expression were both higher in CD4+ T cells from unenriched donor cells compared to the enriched donor cells (B).
Figure 15 shows the vector copy number of TCR in CD4+ and CD8+ T cells. Copies of WPRE and human albumin were measured via qPCR and vector copy number of the TCR was calculated as a ratio of WPRE and human albumin divided by two. Vector copy number of the TCR was higher in both CD4+ T cells and CD8+ T cells from unenriched donor cells than in the enriched donor cells. It is found that the transgene integration was also higher in T cells from apheresis than in enriched T cells, indicated by higher vector copy number.
Figure 16 shows the percentage of leukocytes and leukocyte subsets measured at the end of harvest. All cells were stained for leukocytes (CD45+). Minimal (<1%) B cells (CD19+), NK cells (CD56/16+), and monocytes (CD 14+) were detected in both unenriched and enriched donor cells. Overall the percentage of CD3+ cells (>99%) was comparable between the unenriched and enriched donor cells with the percentage of T cells (CD3+ CD56-) slightly lower in the enriched donor cells due to expansion of NKT cells (CD3+ CD56+).
Figure 17 shows the T cell phenotype at harvest from the enriched- and unenriched- donor cells. This experiment was repeated three times with a different donor samples each time. Among the three donor samples tested, harvested T cells from two donors expressed higher percentage of memory stem cell markers (CD45RA+, CCR7+) and central memory markers (CD45RA-, CCR7+) from unenriched donor cells compared to those cells subject to T cell enrichment. This difference was only significant in CD8+ T cells but not in CD4+ T cells.
Figure 18 shows the growth curve and viability of cells in the bioreactor from enriched- and unenriched- donor cells. Growth (A) and viability (B) were comparable between the enriched- and unenriched- donor cells.
Example 4 This example provides a closed continuous method for producing genetically engineered autologous T cells that express a T cell receptor.
On day 0, a fresh Leukopack® (Hemacare, Northridge, CA), containing 300 ml fresh enriched leukapheresis product collected from normal peripheral blood was sterile welded to a CD-600.1 Sepax Cell
Separation Kit (GE) and processed under Culture Wash-Pro program. The Leukopack® contained leukocytes, erythrocytes, and platelets. The cells were washed in 1L ClinMACS PBS/EDTA, 5ml human serum albumin (Miltenyi Biotec, San Diego, CA) to remove plasma and apheresis buffers using a Sepax CPro equipped with a CS-600.1 Kit (GE Healthcare) according to manufacturer’s instructions. Based on the initial white blood cell (WBC) count indicated on the donor information sheet accompanying the Leukopack®, the cells were eluted at a cell density of 150E6 WBC/ml with ~50 ml OpTimizer complete media.
The nucleated cells in the washed leukapheresed harvest sample were counted using NC-200™ Automated Cell Counter and followed by determining total viable cell count, viability, and immunophenotype of the washed cells.
A sample of the washed apheresed donor cells comprising 1.2E9 nucleated cells was then transferred into a transfer bag (Charter Medicine) under the Dilute program using the Sepax C-Pro processing system with the same CD-600.1 Kit in ~6.5 ml OpTimizer complete media containing 300 ml IL-2 and was incubated with 7.5 ml ImmunoCult™ Human CD3/CD28/CD2 (2.5 pg/ml, Stemcell Technologies) at room temperature for 1 hour at room temperature to allow saturation of antibody binding.
A 2L Xuri SP Perf Cellbag bioreactor (GE Healthcare) was connected to a Xuri Cell Expansion System W25 and 300 ml OpTimizer complete media containing 300 IU IL-2 was added and allowed to equilibrate at 37°C, 5% CO2, gas flow rate of 0.1 L/min, and a rocking rate of 6 rpm at a 6° angle.
The transfer bag was sterile welded to the Xuri Cellbag feed-line and the contents transferred into the bag by gravity. The cells were then incubated overnight at 37°C, 5% CO2, gas flow rate 0.1 L/min at a rocking rate of 2 rpm at a 2° angle, to facilitate activation.
On Day 1, the nucleated cells in the bag were counted. An amount of a lentiviral vector (comprising a polynucleotide encoding a TCR) that corresponded to a MOI of 1 functional titer was diluted in 10ml of OpTimizer complete media containing 300 IU/ml IL2 and was placed in a transfer bag. The transfer bag was sterile welded on to the Xuri Cellbag feed-line and lentiviral vector was transferred into the bioreactor via gravity. The cells were incubated at 37°C, 5% C02, gas flow rate of 0. f L/min, and a rocking rate of 2 rpm at a 2° angle, for 20 - 24 hours.
On Day 2, about half the volume of the culture media in the bioreactor bag was exchanged for fresh OpTimizer complete media including 300 IU/ml IL2 using three 50 ml washouts. Cell counts were taken daily and viable cell density (VCD) and viability were determined using NC200, dissolved oxygen, metabolites were also measured. Cell phenotypes were determined for all samples tested. The bags were maintained on the rocking bioreactors at 2 rpm at a 2° angle, 37°C, 5% CO2, gas flow rate of O.f L/min, for 24 hours.
On Days 3-10 the culture was maintained at 300 ml OpTimzer complete media including 300 IU/ml IL2 by perfusion feeding at rate of one bag volume per day, with a rocking rate of 2 rpm at a 2° angle, at 37°C, 5% CO2, with gas flow rate of 0.1 L/min, until the cell density reached 4e6 cells/ml.
At that point, the volume of the culture media was increased to 600 ml, perfusing at a rate of one bioreactor bag per day, with a rocking rate of 4 rpm at a 4° angle, at 37°C, 5% CO2, with gas flow rate of 0.1 L/min, until the cell density again reached 4e6 cells/ml.
At that point the volume of the culture media was increased to 1000 ml, perfusing at a rate of one bioreactor bag per day, with a rocking rate of 6 rpm at a 6° angle, at 37°C, 5% CO2, with gas flow rate of 0.1 L/min, until harvest on Day 10.
Total viable cell density, viability, glucose and lactate measurements were taken each day. Phenotyping was determined on days 3, 5 and 7.
The cells were harvested on Day 10. The Xuri SP Per bioreactor bag was sterile welded to a Selfia 5200 Cell Processing System using the FlexCell program and CT-800.1 Cell Processing kit (GE Healthcare,). The T cell were concentrated to ~20ml at a 75ml/min flow rate. One wash cycle was performed using 0.9% saline (Baxter, Deerfield, Ill) supplemented with 1% vol human serum albumin (HSA). The wash was performed at 380 X g for 5 min. The wash was performed at 380 X g for 5 min.
The cells were then eluted at 2e8 cells/ml in saline supplemented with 1% HSA and were further formulated at a 1:1 ratio with Hy Clone™ Cryopreservation Media (GE Healthcare) supplemented with 5% human serum albumin. Final cell product was then split into two freezing bags and several cryovials, which were finally frozen down in VIA Freeze™ Quad freezer (GE) with a cooling rate of -l°C/min until the temperature reached -80°C. After freezing, cells were transferred to liquid nitrogen for long-term storage.
Results
Figure 19 shows the growth curve and viability of cells. The dip in viability is likely due to gradual die off of non-T cells.
Figure 20 shows the percentage of leukocyte subsets at DayO and Day 10. The cells were stained with an antibody cocktail targeting B cells (CD19), Monocytes (CD14), T cells (CD3+, CD56/16-), NKT cells (CD3+, CD56/16+), NK cells (CD3-, CD56+), CD4 T cells (CD3+, CD4+), and CD8 T cells (CD3+, CD8+) and analyzed by flow cytometry. CD3 cell purity reached 98% with total T cells at 98% and NKT cells at 10% by the time of harvest (10 days).
Figure 21 shows T cell differentiation during bioprocessing. T cells subsets Tscm (CD45RA+, CD45RO-, CCR7+, CD95+), Tcm (CD45RA-, CD45RO+, CCR7+, CD95+), and Tem (CD45RA-, CD45RO+, CCR7-, CD95+) were stained with antibody cocktail and analyzed by flow cytometry at
different timepoints. T cells differentiated similarly to that shown in in Examples 1 and 2 with around 70% Tem and around 30% Tscm+Tcm by the time of harvest.
Figure 22 shows the expression of transgene in harvested T cells at cell surface level (A) and DNA level (B). Dextramer staining was performed to qualify surface expression of transgene on transduced and untransduced T cells. Transgene expression was over 50% on transduced T cells (A). DNA was extracted from harvested cells and 2 ng DNA was used for qPCR reactions targeting WPRE and human albumin. Vector copy number was calculated as a ratio of copy number of WPRE and copy number of human albumins divided by 2. No detectable copy of transgene was found in untransduced T cells and copy number of transgene in transduced T cells was under 5, within the guideline on vector copy number implemented by FDA (B).
Figure 23 shows the percentage of killing of target cells at different effector to target cells (E:T) ratios. Harvested T cells (transduced or un-transduced) were co-cultured with target cells for 24 hours at E:T ratio at 1:1, 1:5, and 1:10. Percentage of killing of target cells was calculated by the percentage of cell death of target cells after 24 hours of co-culture. Transduced T cells showed strong killing of target cells (>70%) at all E:T ratio tested.
Figure 24 shows IFN-gamma release of harvested cells. Harvested cells (transduced and untransduced) were co-cultured with target cells pulsed with different concentrations of peptide for 24 hours. IFN-gamma in the supernatant was measured via Alphalisa assay. Similar level of IFN-gamma was seen in Example 1 and 2.
The closed continuous autologous process generated over 26 billion engineered T cells rapidly (10 days), with high transgene expression (>50%) and CD3 cell purity (98%). The engineered T cells exhibited remarkable killing potency against target cells at low effector to target cells ratio (1:10) possibly resulting from robust IFN-gamma release in response to target cells.
Example 5 Assessing transduction efficiency of a T cell expressing a TCR after stimulation with different reagents
On day 0, half of afresh Leukopack® (Hemacare, Northridge, CA), containing 150 ml leukapheresis product collected from normal peripheral blood was sterile welded to a CD-600.1 Sepax Cell Separation Kit (GE) and processed under Culture Wash-Pro program. The Leukopack® contained leukocytes, erythrocytes, and platelets. The cells were washed in 1L ClinMACS PBS/EDTA, 5ml human serum albumin (Miltenyi Biotec, San Diego, CA) to remove plasma and apheresis buffers using a Sepax C-Pro Cell Separation System equipped with a CS-600.1 Kit (GE Healthcare), according to manufacturer’s instructions.
The nucleated cells in the harvest sample were counted using NC-200™ Automated Cell Counter (ChemoMetec) and followed by determining total viable cell count, viability, and immunophenotype of the washed cells.
Starting populations of cells were prepared either by isolating pan T cells from the washed cells donor cells using an Easy Sep™ Human pan T negative selection kit (Stemcell Technologies) according to the manufacturer’s instructions or using the washed donor cells without further selection or enrichment, “unenriched cells”. The enriched pan T cells and the unenriched cells were resuspended in OpTmizer complete media containing 300 IU/ml IL2 (Stemcell Technologies), unless otherwise noted, and added to transfer bags. In some experiments IL-7, IL-15, IL-21, and/or TWS1119 (Stemcell Technologies) were used in the activation and expansion media.
Gas-permeable bags (PL07, Permalife, OriGen, Austin, TX) were prepared by coating with lug/mL anti-CD3 (Clone OKT3 Miltenyi Biotech, Cambridge, MA) in PBS at 4° overnight and washed with PBS before adding cells. The following conditions were tested:
1) In one experiment, isolated pan T cells (2xl06 cells/mL) were inoculated into anti-CD3 coated bags in OpTmizer complete media containing 300 IU/ml IL2 (Stemcell Technologies) and lpg/ml anti- CD28 (Miltenyi). For the titration of anti-CD3 or starting cell number, anti-CD3-coated plates (Coming) were used. The plates were coated with anti-CD3 at a titrated concentration from 0.0001 - 10 pg/ml. The cells were activated for 20 hours and 48 hours. These cells were not transduced. The levels of CD69, CD25, and 4-1BB on CD3+ T cells was measured by flow cytometry at 20 and 48 hours (2 replicates per condition).
2) To compare the different activators, isolated pan T cells (2xl06 cells/mL) were inoculated into anti-CD3 coated bag in OpTmizer complete media containing 300 IU/ml IL2 (Stemcell Technologies) and lug/ml anti-CD28 (Miltenyi). The following soluble activators were tested against the coated anti-CD3 condition: Immunocult anti-CD3/CD28 (Stemcell Technologies, Cambridge, MA), and Immunocult anti- CD3/CD28/CD2 (Stemcell Technologies), each at 25uL activator per lmL of medium at 2E6 cells/mL, following the manufacturer’s instructions. Dynabeads™ Human T-Activator CD3/CD28 (ThermoFisher) at a 1:1 beadsxells ratio, following manufacturer’s instructions, was tested in an uncoated bag. The cells/activators were incubated for 20 hours and 48 hours.
3) Isolated pan T cells (2xl06 cells/mL) were inoculated into anti-CD3 coated gas-permeable bags from above, in OpTmizer complete media containing 300 IU/ml IL2 (Stemcell Technologies) and lug/ml anti-CD28 (Miltenyi). The following activators were tested: lug/mL coated anti-CD3 gas permeable bags from above with lug/mL. Soluble anti-CD28 (Miltenyi), soluble Immunocult anti-CD3/CD28/CD2 (Stemcell Technologies), at 25uL activator per lmL of medium, Dynabeads™ Human T-Activator CD3/CD28 (ThermoFisher) at a 1:1 beadsxells ratio, and soluble MACS® GMP T Cell TransAct™ anti- CD3 and anti-CD28 conjugated polymeric nanomatrix, (Miltenyi Biotech) at a concentration of (1:17.5
dilution), were tested in uncoated bags 48 hours after activation, the cells from the coated anti-CD3 bag were transferred to a new bag to remove the stimulation. Following activation, the cells were transduced, as described below. The cells/activators were incubated for 7 days. Engineered TCR expression was assessed by flow cytometry using a dextramer recognizing the peptide-MHC class I complex, gated on CD8+ T cells.
4) Washed leukaphereased cells (2xl06 cells/mL) were inoculated into the anti-CD3 coated gas- permeable bags from above in OpTmizer complete media containing 300 IU/ml IL2 (Stemcell Technologies) and lug/ml anti-CD28 (Miltenyi). The following activators were tested: lug/mL coated anti-CD3 (Miltenyi) with lug/mL soluble anti-CD28 (Miltenyi) and soluble Immunocult anti- CD3/CD28/CD2 (Stemcell Technologies), at 25uL activator per lmL of medium. 48 hours after activation, the cells from the coated anti-CD3 bag were transferred to a new bag to remove the stimulation. Following activation, the cells were transduced, as described below. The cells/activators were incubated for 7 days. Transduction efficiency was assessed by flow cytometry using GFP expression, gating on either CD8+ or CD4+ T cells.
5) The effect of different cytokine cocktails. Fresh cells from the Leukopheresed material (WLPCs) were activated at 2xl06 cells/mL in gas permeable bags with Immunocult anti-CD3/CD28/CD2 (Stemcell Technologies) in OpTmizer complete media containing 4 different cytokine cocktails: a) 300 IU/ml IL2, b) lOng/mL IL-7 (Stemcell Technologies) and lOng/mL IL-15 (Stemcell Technologies), c) lOuM TWS119 (Stemcell Technologies), lOng/mL IL-7 (Stemcell Technologies), and 20ng/mL IL-21 (Stemcell Technologies), or d) lOng/mL IL-7 (Stemcell Technologies) and 20ng/mL IL-21 (Stemcell Technologies). Engineered TCR expression was assessed by flow cytometry using a dextramer specific to the TCR (Immudex), gating on CD8+ T cells.
6) The effect of starting WLPC density for activation with soluble activator. Cells were activated with Immunocult anti-CD3/CD28/CD2 (Stemcell Technologies) in OpTmizer complete media containing 300 IU/mL IL-2 or lOuM TWS119 (Stemcell Technologies) lOng/mL, IL-7 (Stemcell Technologies), and 20ng/mL IL-21 (Stemcell Technologies at 4 different densities: a) lxlO6 cell/mL, b) 2xl06 cell/mL, c) 4xl06 cell/mL, or d) 6x106 cell/mL. Engineered TCR expression was assessed by flow cytometry using a dextramer specific to the TCR (Immudex), gating on CD8+ T cells.
When transduced, 24 hours following activation, the cells in each bag (from experiments 3, 4, 5, and 6 above) were counted. An amount of a lentivirus vector (comprising a polynucleotide encoding a TCR and GFP) that corresponded to a MOI of 1-2 functional titer was added to the bag and incubated overnight at 37°C, 5% C02.
The cells were expanded in static culture in the gas-permeable bags, keeping the cell density between 1-3 million cells/mL by splitting every 2-3 days and transferring to larger gas-permeable bags as needed. The expansion was done for 6-9 days. Media with cytokines were replaced every 2-3 days.
Cell counts were taken every 1-3 days.
Results
Figure 25 shows the results of the titration of coated anti-CD3 (OKT3) antibody and pan T cell activation measured by CD69, CD25, and 4- IBB. Based on the stimulation of the T cells, lug/ml anti-CD3 was chosen for comparison with the soluble activators.
Figure 26 shows the results of stimulation of pan T cells with various soluble activators versus coated anti-CD3 as measured by CD69, CD25, and 4-1BB. Dynabeads (anti-CD3/CD28) showed the strongest stimulation, followed by the Immunocult anti-CD3/CD28/CD2 at the manufacturer’s recommended concentration of 25pL/mL of cells in media. Interestingly, the soluble Immunocult anti- CD3/CD28 activator was comparable to coated anti-CD3.
Figure 27 shows the transduction efficiency of the engineered T cells was dependent on stimulation signal. (A) Starting material: pan T cells. Dextramer staining of the engineered TCR on CD8+ T cells showed Immunocult anti-CD3/CD28/CD2 gave the highest transduction efficiency. (B) Starting material: apheresed cells: FACS for GFP expression in transduced CD4+ and CD8+ T cells showed Immunocult anti-CD3/CD28/CD2 was superior to coated anti-CD3.
Figure 28 shows cell growth was similar between apheresed cells activated coated anti-CD3/soluble anti-CD28, Immunocult anti-CD3/CD28/CD2, TransAct, and Dynabeads for 9 days.
Figure 29 shows culture conditions influenced the transduction efficiency of the engineered T cells. Apheresed cells grown in culture media containing IL-2, he combination of IL-7/15, of the combination of IL-7/21 were similar in transduction efficiency. The cocktail containing IL-7/21/TWS119 improved transduction efficiency.
Figure 30 shows starting cell density had an impact on transduction efficiency. Although there was no effect on the overall growth, higher starting densities of apheresed cells that were activated with Immunocult anti-CD3/CD28/CD2 yielded better transduction efficiencies when culture media contained either IL-2 or a cocktail of IL-7/21/TWS119.
This comparison of different T cell activators and cytokines using two different starting cell populations, enriched pan T cells and leukapheresed cells. Activation strength did not appear to correlate with better transduction efficiency, since Dynabeads anti-CD3/CD28 (ThermoFisher) did not yield high transduction rates despite providing the highest signal strength. Immunocult anti-CD3/CD28/CD2 which had a signal strength higher than coated anti-CD3 but lower than Dynabeads, activated T cells with the highest expression of GFP and the engineered TCR. Activating leukapheresed cells with Immunocult anti- CD3/CD28/CD2 in the presence of different cytokine cocktails had an effect on transduction efficiency, however when compared at different cell densities, transduction of cells activated and grow in culture media
containing IL-2 or IL-7/21/TWS119 were similar. Cells cultured in IL-2 and IL-7/21/TWS119 were compared and it was found that the IL-7/21/TWS119 condition promoted elevated transduction efficiency. These results have important implications for the use of a soluble activator, such as Immunocult anti- CD3/CD28/CD2, in a manufacturing process that leads to high numbers of functional engineered T cells for cell therapy applications.
Example 6 Optimum MOI for TCR Transduction
Previously frozen apheresed cells were thawed and activated with Immunocult CD3/CD28/CD2 (25 mΐ/ml of cells, Stemcell Technologies) for 24 hours, as described above. On day 1 post activation, a lentiviral vector comprising a polynucleotide encoding a TRC was added to lxlO6 cells at an increased multiplicity of infection (MOI) (A), equal to or greater than a MOI of 1, or (B) decreasing MOIs of 2 or less. Cells were assayed for TCR expression 7 days post-transduction. No observable MOI effect was observed at MOIs greater than 1. Reported values are averages of TCR expression in CD8+ T cells from 4 different donors. Figures 30A and 7B show the MOI of 1 was optimal for lentiviral transduction in large- scale, closed bioprocess.
Claims (67)
1. A method for producing genetically engineered autologous T cells expressing at least one protein of interest, the method comprising inoculating a closed single use bioreactor bag containing culture media with apheresed donor cells and one or more soluble T cell activators, wherein the bioreactor bag is part of a rocking bioreactor platform, culturing the cells in the closed single use bioreactor bag continuously rocking at a rate of about 2
RPM, transducing the cells in the closed single use bioreactor bag with at least one soluble viral vector comprising a polynucleotide which encodes the protein of interest continuously rocking at a rate of about 2 RPM, and expanding the cells in the closed single use bioreactor bag at a rocking rate of about 2 RPM and increasing the culture volume and rocking rate as needed to maintain the culture until harvest.
2. The method of claim 1, wherein the apheresed donor cells comprise cells from peripheral blood.
3. The method of claim 2, wherein the apheresed donor cells comprise nucleated and non-nucleated cells.
4. The method of claim 1, wherein the apheresed donor cells comprise leukocytes and erythrocytes.
5. The method of claim 4, wherein the apheresed donor cells also comprise granulocytes and/or platelets.
6. The method of claim 1, wherein the apheresis is leukapheresis.
7. The method of claim 1, wherein the apheresed donor cells are washed and resuspended in a culture media.
8. The method of claim 1, wherein at least one T cell activator is an anti CD3 antibody or binding fragments thereof.
9. The method of claim 1, wherein the T cell activator comprises an anti CD3 antibody and an anti CD28 antibody, or binding fragments thereof.
10. The method of claim 1, wherein the T cell activator comprises at least an anti CD3 antibody, an anti CD28 antibody, and an anti CD2 antibody, or binding fragments thereof.
11. The method of claim 1, wherein the T cell activator comprises at least an anti-human CD3 monospecific tetrameric antibody complex, an anti-human CD28 monospecific tetrameric antibody complex, and an anti human CD2 monospecific tetrameric antibody complex.
12. The method of claim 1, wherein the concentration of at least one soluble T cell activator is at least 0.001 pg/ml to at least 10 pg/ml.
13. The method of claim 12, wherein the concentration of at least one soluble T cell activator is at least 0.1 pg/ml to at least 5 pg/ml.
14. The method of claim 1, wherein at least one soluble T-cell activator is bound to at least one donor cell at the time of inoculation.
15. The method of claim 1, wherein the apheresed donor cells are incubated with one or more soluble T cell activators prior to inoculating into the bioreactor bag.
16. The method of claim 15, wherein the incubation is for a sufficient time to allow for saturation of binding of one or more soluble T cell activator to the apheresed donor cells prior to inoculation.
17. The method of claim 16, wherein the apheresed donor cells and one or more soluble T cell activators are incubated in a transfer bag.
18. The method of claim 17, wherein the volume of culture media in the transfer bag is about 5 ml to about 50 ml.
19. The method of claim 18, wherein the volume of culture media in the transfer bag is about 5 ml to about 10 ml.
20. The method of claim 17, wherein the apheresed donor cells are incubated with one or more T cell activators for at least 30 minutes or more.
21. The method of claim 20, wherein the apheresed donor cells are incubated with one or more T cell activators for at least 1 hour.
22. The method of claim 1, wherein the number of nucleated cells within the apheresed donor cells is about 1.0E9 to about 1.3E9.
23. The method of claim 1, wherein the number of nucleated cells within the apheresed donor cells is about 1.2E9.
24. The method according to claim 1, wherein the bioreactor bag is inoculated with apheresed donor cells at a cell density of about 1E6 to about 5E6 nucleated cells/ml.
25. The method according to claim 24, wherein the bioreactor bag is inoculated with apheresed donor cells at a cell density of about 2E6.
26. The method according to claim 1, wherein the bioreactor bag contains at least 300 ml to at least 400 ml of culture media at inoculation.
27. The method according to claim 26, wherein the bioreactor bag contains at least 300 ml of culture media at inoculation.
28. The method according to claim 1, wherein the apheresed donor cells are cultured in the bioreactor bag for about 12-24 hours.
29. The method of claim 1, wherein the culture media comprises at least one soluble cytokine.
30. The method according to claim 29, wherein the soluble cytokine selected from IL-2, IL-7, IL-15, or IL- 21
31. The method according to claim 29, wherein at least one soluble cytokine is IL-2.
32 The method according to claim 29, wherein the IL-2 is at a concentration of about 250 IU/ml to about 350 IU/ml.
33. The method according to claim 32, wherein the IL-2 is at a concentration of about 300 IU/ml.
34. The method according to claim 29, wherein the soluble cytokine is IL-7 in combination with IL-15 or IL-21.
35. The method according to claim 29, wherein the concentration of at least one cytokine is at least 5ng/ml to at least 30ng/ml.
36. The method according to claim 35, wherein the concentration of at least one cytokine is at least lOng/ml to at least 20ng/ml.
37. The method according to claim 1, wherein the culture media also comprises a WNT pathway activator.
38. The method according to claim 37, wherein the WNT pathway activator is TWS117.
39. The method according to claim 37, wherein the culture media comprises a mixture of soluble TWS117, IL-7, and IL-21.
40. The method of claim 1, wherein the culture media also comprises a soluble glycolysis inhibitor.
41. The method of claim 40, wherein the soluble glycolysis inhibitor is 2-deoxy-D-glucose (2-DG).
42. The method of claim 1, wherein the viral vector is a retroviral vector.
43. The method of claim 1, wherein the viral vector is a lentiviral vector.
44. The method of claim 1, wherein the lentiviral vector is added at a MOI of 0.25 - 10.
45. The method of claim 1, wherein the lentiviral vector is added at a MOI of 1.
46. The method of claim 44, wherein the cells are transduced for about 20-24 hours.
47. The method of claim 1, wherein following transduction, half of the culture media is removed from the bioreactor bag and replaced with an equal volume of fresh culture media.
48.The method of claim 47, wherein the culture is incubated for about 12-24 hours.
49. The method of claim 1, wherein during expansion, fresh culture media is added to the bioreactor by fed batch/perfusion feeding and/or by perfusion.
50. The method of claim 1, wherein during expansion the culture is perfused at a rate is one bioreactor bag volume per day.
51. The method of claim 1, as the cells are expanded the volume of the culture media in bioreactor is incrementally increased to 1 liter during expansion.
52. The method of claim 1, as the cells are expanded the volume of the culture media is incrementally increased to maintain a cell density of at least 2E6 nucleated cells/ml.
53. The method of claim 1, as the cells are expanded the volume of the culture media in bioreactor is incrementally increased to 1 liter during expansion to maintain a cell density of at least 4E6 nucleated cells/ml.
54. The method of claim 1, as the cells are expanded the rocking rate is incrementally increased to 6 RPM.
55. The method of claim 1, at the start of expansion the volume of culture media in the single use closed bioreactor bag is 300 ml rocking at a rate of 2 rpm at a 2° angle.
56. The method of claim 1, wherein the culture in the single use closed bioreactor bag is maintained at about 80 - 100% 02.
57. The method of claim 1, wherein the cells are expanded for 7 to 14 days.
58. The method of claim 1, wherein the culture, transduction, and/or expansion steps are performed at 34- 37°C.
59. The method of claim 1, wherein the protein of interest is a cell surface receptor.
60. The method of claim 59, wherein the cell surface receptor a T cell receptor, or chimeric antigen receptor.
61. The method of claim 60, wherein the cell surface receptor recognizes an antigenic target associated with a target cell.
62. The method of claim 61, wherein the target cell is a cancer cell.
63. The method of claim 1, wherein the genetically engineered autologous T cells are used to treat an indication in a patient in need.
64. A pharmaceutical composition comprising the genetically engineered autologous T cells of claim 1.
65. A method of treating an indication in a patient in need, comprising administering to the patient the pharmaceutical composition of claim 64.
66. A method for increasing the transgene expression in genetically engineered autologous T cells expressing a protein of interest, the method comprising inoculating a closed single use bioreactor bag containing culture media with apheresed donor cells and one or more soluble T cell activators, wherein at least one soluble T-cell activator is bound to at least one donor cell at the time of inoculation and the bioreactor bag is part of a rocking bioreactor platform, culturing the cells in the closed single use bioreactor bag continuously rocking at a rate of about 2
RPM, transducing the cells in the closed single use bioreactor bag with at least one soluble viral vector comprising a polynucleotide which encodes the protein of interest continuously rocking at a rate of about 2 RPM, and expanding the cells in the closed single use bioreactor bag at a rocking rate of about 2 RPM and increasing the culture volume and rocking the rate as needed to maintain the culture until harvest, wherein the transgene expression is greater than the transgene expression of genetically engineered autologous T cells derived from an enriched population of T cells from the same apheresed donor cells and expressing the same protein of interest.
67. A method of treating a patient with genetically engineered autologous T cells expressing a protein of interest comprising,
incubating apheresed cells from the patient with one or more T cell activators selected from the group consisting of an anti CD3 antibody, an anti CD2 antibody, and an anti CD28 antibody or binding fragments thereof, to allow for saturation of antibody binding, inoculating a closed single use bioreactor bag containing culture media with the apheresed cells, wherein the bioreactor bag is part of a rocking bioreactor platform, culturing the cells in the closed single use bioreactor bag continuously rocking at a rate of about 2
RPM, transducing the cells in the closed single use bioreactor bag with at least one soluble viral vector comprising a polynucleotide which encodes the protein of interest continuously rocking at a rate of about 2 RPM, and expanding the cells in the closed single use bioreactor bag at a rocking rate of about 2 RPM, increasing the culture volume and rocking the rate as needed to maintain the culture at a desired cell density until harvest. harvesting and formulating the cells for cryopreservation, freezing the cells and storing until needed for administering to the patient, thawing and resuspending the cells in a suitable media for infusion, and reintroducing a pharmaceutically effective amount of the genetically engineered autologous T cells expressing the protein of interest into the patient.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2020/028192 WO2021211104A1 (en) | 2020-04-15 | 2020-04-15 | Process for generating genetically engineered autologous t cells |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2020442490A1 true AU2020442490A1 (en) | 2022-11-17 |
Family
ID=70476574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2020442490A Pending AU2020442490A1 (en) | 2020-04-15 | 2020-04-15 | Process for generating genetically engineered autologous T cells |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4135724A1 (en) |
JP (1) | JP2023522642A (en) |
AU (1) | AU2020442490A1 (en) |
CA (1) | CA3180143A1 (en) |
MX (1) | MX2022012990A (en) |
WO (1) | WO2021211104A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210324333A1 (en) * | 2020-04-15 | 2021-10-21 | Amgen Inc. | Method for enhancing production of genetically engineered autologous t cells |
WO2022140321A2 (en) | 2020-12-22 | 2022-06-30 | Amgen Inc. | Mage-b2-specific t-cell receptors |
WO2023121937A1 (en) | 2021-12-21 | 2023-06-29 | Amgen Inc. | Dcaf4l2-specific t-cell receptors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US7572631B2 (en) * | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
AU2015214145A1 (en) * | 2014-02-04 | 2016-08-25 | Kite Pharma. Inc. | Methods for producing autologous T cells useful to treat B cell malignancies and other cancers and compositions thereof |
GB201509202D0 (en) * | 2015-05-28 | 2015-07-15 | Ge Healthcare Bio Sciences Ab | Semi-static cell culture |
US12053490B2 (en) * | 2017-10-26 | 2024-08-06 | St. Jude Children's Research Hospital, Inc. | Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cells |
-
2020
- 2020-04-15 JP JP2022562462A patent/JP2023522642A/en active Pending
- 2020-04-15 MX MX2022012990A patent/MX2022012990A/en unknown
- 2020-04-15 CA CA3180143A patent/CA3180143A1/en active Pending
- 2020-04-15 AU AU2020442490A patent/AU2020442490A1/en active Pending
- 2020-04-15 EP EP20722966.7A patent/EP4135724A1/en active Pending
- 2020-04-15 WO PCT/US2020/028192 patent/WO2021211104A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3180143A1 (en) | 2021-10-21 |
EP4135724A1 (en) | 2023-02-22 |
JP2023522642A (en) | 2023-05-31 |
WO2021211104A1 (en) | 2021-10-21 |
MX2022012990A (en) | 2023-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7470640B2 (en) | Methods for Producing T Cells | |
US20230190814A1 (en) | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy | |
CN107922925B (en) | Method for natural killer cell expansion | |
US20210324333A1 (en) | Method for enhancing production of genetically engineered autologous t cells | |
CN112639083A (en) | Method for producing cells expressing chimeric antigen receptor | |
US9670459B2 (en) | Production method for cell populations | |
AU2020442490A1 (en) | Process for generating genetically engineered autologous T cells | |
Zhou et al. | iCaspase 9 suicide gene system | |
US20210324331A1 (en) | Process for generating genetically engineered autologous t cells | |
US20200297768A1 (en) | Cd28 t cell cultures, compositions, and methods of using thereof | |
GB2484869A (en) | Pharmaceutical composition containing transiently surviving CTL | |
EP3941487B1 (en) | Cd28 t cell cultures, compositions, and methods of using thereof | |
CN111206052B (en) | Trophoblast, preparation method thereof and application thereof in large-scale rapid amplification of gamma delta T cells | |
US20240117309A1 (en) | Methods for expanding t cell populations | |
US20240271095A1 (en) | Production of engineered t cells from stem cells | |
TW202426632A (en) | Methods and systems for production of engineered t-cells | |
Class et al. | Patent application title: METHOD FOR NATURAL KILLER CELL EXPANSION | |
AU2022366817A1 (en) | Engineering stem cell t cells with multiple t cell receptors | |
WO2024097787A2 (en) | Methods and systems for production of engineered t-cells | |
EP4351598A1 (en) | Engineering stem cells for allogenic car t cell therapies |